

Niraparib in Patients with Newly Diagnosed Advanced

New England Journal of Medicine

381, 2391-2402

DOI: [10.1056/nejmoa1910962](https://doi.org/10.1056/nejmoa1910962)

Citation Report

#	ARTICLE	IF	CITATIONS
1	CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 113.	6.9	69
2	Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something?. <i>Annals of Translational Medicine</i> , 2019, 7, S372-S372.	0.7	5
3	Emerging serine-threonine kinase inhibitors for treating ovarian cancer. <i>Expert Opinion on Emerging Drugs</i> , 2019, 24, 239-253.	1.0	6
4	Cancer biomarkers for targeted therapy. <i>Biomarker Research</i> , 2019, 7, 25.	2.8	72
5	Translational Highlights in Breast and Ovarian Cancer 2019 “ Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1309-1319.	0.8	11
6	Personalized Medicine for Primary Treatment of Serous Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2471-2474.	13.9	27
8	Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer. <i>JAMA Network Open</i> , 2020, 3, e1918939.	2.8	40
9	A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 689-694.	0.6	16
10	Metallointercalator [Ru(dppz)2(PIP)]2+ Renders BRCA Wild-Type Triple-Negative Breast Cancer Cells Hypersensitive to PARP Inhibition. <i>ACS Chemical Biology</i> , 2020, 15, 378-387.	1.6	12
11	Latest clinical evidence of maintenance therapy in ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 15-21.	0.9	19
12	Mechanisms of PARP inhibitor resistance in ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 36-41.	0.9	21
13	Delving into PARP inhibition from bench to bedside and back. , 2020, 206, 107446.		11
14	Maintenance Therapy in the Primary Treatment of Epithelial Ovarian Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 80-85.	0.6	0
15	Clinical assays for assessment of homologous recombination DNA repair deficiency. <i>Gynecologic Oncology</i> , 2020, 159, 887-898.	0.6	70
16	Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network. <i>Journal of Clinical Pathology</i> , 2020, 74, jclinpath-2020-206800.	1.0	3
17	Newly diagnosed ovarian cancer: Which first-line treatment?. <i>Cancer Treatment Reviews</i> , 2020, 91, 102111.	3.4	23
18	Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 581-587.	0.6	9
19	Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy. <i>International Journal of Pharmaceutics</i> , 2020, 591, 119986.	2.6	30

#	ARTICLE	IF	CITATIONS
20	Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 159, 381-386.	0.6	10
21	Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. <i>Life Sciences</i> , 2020, 261, 118434.	2.0	23
22	Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. <i>Nature Communications</i> , 2020, 11, 5173.	5.8	46
23	Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2020, 12, 3026.	1.7	11
24	Years of life lost due to premature death and their trends in people with malignant neoplasm of female genital organs in Shanghai, China during 1995â€”2018: a population based study. <i>BMC Public Health</i> , 2020, 20, 1489.	1.2	15
25	Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. <i>Gynecologic Oncology</i> , 2020, 159, 442-448.	0.6	28
26	High-throughput approaches for precision medicine in high-grade serous ovarian cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 134.	6.9	36
27	Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma. <i>Pharmaceuticals</i> , 2020, 13, 287.	1.7	0
28	ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. <i>Annals of Oncology</i> , 2020, 31, 1606-1622.	0.6	238
29	Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?. <i>EBioMedicine</i> , 2020, 61, 103046.	2.7	7
30	Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. <i>European Journal of Cancer</i> , 2020, 139, 59-67.	1.3	12
31	Role of delayed interval debulking for persistent residual disease after more than 5Â cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. <i>Gynecologic Oncology</i> , 2020, 159, 434-441.	0.6	16
32	Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 445-453.	1.0	15
33	The DNA damaging revolution. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103117.	2.0	9
34	Cost-effectiveness analysis comparing â€œPARP inhibitors-for-allâ€ to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 483-490.	0.6	19
35	Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance. <i>Gynecologic Oncology</i> , 2020, 159, 604-606.	0.6	3
36	Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. <i>European Journal of Human Genetics</i> , 2020, 28, 1541-1547.	1.4	22
37	GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer. <i>Anticancer Research</i> , 2020, 40, 3939-3945.	0.5	7

#	ARTICLE	IF	CITATIONS
40	Five-year survival decreases over time in patients with BRCA-mutated ovarian cancer: a systemic review and meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 48-54.	1.2	8
41	Insight updating of the molecular hallmarks in ovarian carcinoma. <i>European Journal of Cancer, Supplement</i> , 2020, 15, 16-26.	2.2	12
42	DNA damaging agents in ovarian cancer. <i>European Journal of Cancer, Supplement</i> , 2020, 15, 67-72.	2.2	2
43	Gemogenovatumel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. <i>Lancet Oncology</i> , The, 2020, 21, 1661-1672.	5.1	69
44	Adherence to Oral Anticancer Therapeutics in the Gynecologic Oncology Population. <i>Obstetrics and Gynecology</i> , 2020, 136, 1145-1153.	1.2	10
45	Landmark studies of therapeutic vaccination in cervical and ovarian cancers. <i>Lancet Oncology</i> , The, 2020, 21, 1549-1550.	5.1	2
46	Measuring Quality of Life in Ovarian Cancer Clinical Trials—Can We Improve Objectivity and Cross Trial Comparisons?. <i>Cancers</i> , 2020, 12, 3296.	1.7	13
47	Targeting progesterone signaling prevents metastatic ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 31993-32004.	3.3	29
48	PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches. <i>Journal of Thoracic Disease</i> , 2020, 12, 6240-6252.	0.6	26
49	Treatment of epithelial ovarian cancer. <i>BMJ</i> , The, 2020, 371, m3773.	3.0	359
50	Effects of initiating physician-performed germline testing in safety net clinic patients with epithelial ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2020, 34, 100662.	0.3	0
51	Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3528-3537.	0.8	64
52	Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis. <i>Cancers</i> , 2020, 12, 2156.	1.7	27
53	Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement. <i>Gynecologic Oncology</i> , 2020, 159, 8-12.	0.6	18
54	Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2020, 12, 2184.	1.7	17
55	Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population. <i>Gynecologic Oncology</i> , 2020, 159, 58-65.	0.6	20
56	<p>PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6123-6135.	0.9	25
57	<p>First-Line Treatment Âwith OlaparibÂfor Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5479-5489.	0.9	3

#	ARTICLE	IF	CITATIONS
58	Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 137.	7.1	79
59	PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies. <i>Cancers</i> , 2020, 12, 2054.	1.7	43
60	PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials. <i>Frontiers in Oncology</i> , 2020, 10, 1204.	1.3	13
61	Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study. <i>Gynecologic Oncology</i> , 2020, 159, 95-100.	0.6	10
62	PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094411.	1.4	34
63	Financial Toxicity Encountered in Therapeutic Radiopharmaceutical Clinical Development for Ovarian Cancer. <i>Pharmaceuticals</i> , 2020, 13, 181.	1.7	2
64	PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 3468-3493.	0.8	175
65	XRCC1 promotes replication restart, nascent fork degradation and mutagenic DNA repair in BRCA2-deficient cells. <i>NAR Cancer</i> , 2020, 2, zcaa013.	1.6	36
66	Clinical Utility of Preoperative Assessment in Ovarian Cancer Cytoreduction. <i>Diagnostics</i> , 2020, 10, 568.	1.3	6
69	Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment. <i>Cancer Treatment Reviews</i> , 2020, 90, 102107.	3.4	21
70	Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer. <i>Cancers</i> , 2020, 12, 3046.	1.7	22
71	Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. <i>Scientific Reports</i> , 2020, 10, 18190.	1.6	16
72	The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?. <i>Cancers</i> , 2020, 12, 3129.	1.7	29
73	Single-cell analysis of copy-number alterations in serous ovarian cancer reveals substantial heterogeneity in both low- and high-grade tumors. <i>Cell Cycle</i> , 2020, 19, 3154-3166.	1.3	13
74	A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer. <i>Journal of Ovarian Research</i> , 2020, 13, 101.	1.3	10
75	Frontline Management of Epithelial Ovarian Cancer—Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research. <i>Journal of Clinical Medicine</i> , 2020, 9, 2830.	1.0	4
76	Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer. <i>Future Oncology</i> , 2020, 16, 2701-2711.	1.1	1
77	PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?. <i>Medicines (Basel, Switzerland)</i> , 2020, 7, 54.	0.7	21

#	ARTICLE	IF	CITATIONS
79	DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1824-1828.	1.2	6
80	The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1608-1618.	1.2	4
81	PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies. <i>Chinese Clinical Oncology</i> , 2020, 9, 51-51.	0.4	4
82	Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer. <i>Drugs</i> , 2020, 80, 1525-1535.	4.9	8
83	Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?. <i>Current Opinion in Oncology</i> , 2020, 32, 442-450.	1.1	10
84	Front-Line Maintenance Therapy in Advanced Ovarian Cancerâ€”Current Advances and Perspectives. <i>Cancers</i> , 2020, 12, 2414.	1.7	10
85	Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 1087-1102.	0.8	31
86	Poly (ADP-Ribose) Polymerase Inhibitor Activity in Prostate Cancers Harboring Mutations in DNA Repair Genes: Who Benefits?. <i>JCO Precision Oncology</i> , 2020, 4, 1034-1037.	1.5	6
87	Clinical implications of nextâ€“generation sequencingâ€“based panel tests for malignant ovarian tumors. <i>Cancer Medicine</i> , 2020, 9, 7407-7417.	1.3	23
88	Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1569-1575.	1.2	10
89	Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1576-1582.	1.2	9
90	PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 564601.	1.8	315
91	Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer â€“ Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 932-940.	0.8	7
92	Breast cancer (BRCA) gene testing in ovarian cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 63-63.	0.4	3
93	A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. <i>Pharmacoeconomics</i> , 2020, 38, 1201-1218.	1.7	5
94	PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts. <i>BMC Cancer</i> , 2020, 20, 775.	1.1	20
95	First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion. <i>ESMO Open</i> , 2020, 5, e001110.	2.0	42
96	Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer. <i>Tumor Biology</i> , 2020, 42, 101042832097140.	0.8	6

#	ARTICLE	IF	CITATIONS
97	Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil [®] in frontline maintenance. <i>Gynecologic Oncology Reports</i> , 2020, 34, 100648.	0.3	15
98	Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIRO2-Lung Trial. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100068.	0.6	10
99	LRH1 Promotes Tumor Cell Proliferation and Migration and Is Correlated With Poor Prognosis in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 583566.	1.3	1
100	Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures. <i>Cancers</i> , 2020, 12, 3256.	1.7	8
102	Streamlining genetic testing for women with ovarian cancer in a Northern California health care system. <i>Gynecologic Oncology</i> , 2020, 159, 221-228.	0.6	10
103	Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 888-892.	1.2	59
104	PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e116-e131.	1.8	30
106	Therapeutic applications of PARP inhibitors in ovarian cancer. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 110204.	2.5	29
107	Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform. <i>Oncologist</i> , 2020, 25, e1060-e1069.	1.9	4
108	Immunology and ovarian cancers. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 425-432.	0.6	28
110	Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 491-502.	1.1	2
111	Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1206.	1.7	6
112	Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. <i>Gynecologic Oncology</i> , 2020, 158, 16-24.	0.6	40
113	Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2020, 87, 102040.	3.4	35
114	Biomarker-Guided Development of DNA Repair Inhibitors. <i>Molecular Cell</i> , 2020, 78, 1070-1085.	4.5	157
115	Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3805.	1.8	17
116	High resolution melting profiles (HRMPs) obtained by magnetic induction cyler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment. <i>Molecular Biology Reports</i> , 2020, 47, 4897-4903.	1.0	0
117	Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas. <i>Cancers</i> , 2020, 12, 1315.	1.7	18

#	ARTICLE	IF	CITATIONS
118	PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?. <i>Frontiers in Oncology</i> , 2020, 10, 782.	1.3	11
119	PARP inhibitor resistance: the underlying mechanisms and clinical implications. <i>Molecular Cancer</i> , 2020, 19, 107.	7.9	235
120	Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 165-188.	1.0	10
121	First-Line Management of Advanced High-Grade Serous Ovarian Cancer. <i>Current Oncology Reports</i> , 2020, 22, 64.	1.8	30
122	NAD metabolism in aging and cancer. <i>Experimental Biology and Medicine</i> , 2020, 245, 1594-1614.	1.1	17
124	Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092198.	1.4	8
125	The forefront of ovarian cancer therapy: update on PARP inhibitors. <i>Annals of Oncology</i> , 2020, 31, 1148-1159.	0.6	191
126	The emerging role of precision medicine in the treatment of ovarian cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 283-297.	0.4	3
127	Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication. <i>Future Oncology</i> , 2020, 16, 1751-1766.	1.1	20
128	Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1607.	1.7	104
129	PARP inhibitors in the treatment of ovarian cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 198-201.	0.3	1
130	Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2020, 157, 599-605.	0.6	5
131	Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. <i>Drugs in R and D</i> , 2020, 20, 55-73.	1.1	84
132	Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 295.	1.3	21
133	CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4625-4632.	3.2	47
134	30 Years of Experience in the Management of Stage III and IV Epithelial Ovarian Cancer: Impact of Surgical Strategies on Survival. <i>Cancers</i> , 2020, 12, 768.	1.7	18
135	Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis. <i>Future Oncology</i> , 2020, 16, 585-596.	1.1	13
136	PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. <i>Molecular Cancer</i> , 2020, 19, 49.	7.9	145

#	ARTICLE	IF	CITATIONS
137	Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa026.	1.4	21
138	Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 958.	1.3	9
139	Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy. <i>Cancers</i> , 2020, 12, 1676.	1.7	32
140	Poly-(ADP-ribose) polymerase inhibitors: paradigm shift in the first-line treatment of newly diagnosed advanced ovarian cancer. <i>Pharmacogenomics</i> , 2020, 21, 721-727.	0.6	5
141	Subsequent Development of Epithelial Ovarian Cancer After Ovarian Surgery for Benign Ovarian Tumor: A Population-Based Cohort Study. <i>Clinical Epidemiology</i> , 2020, Volume 12, 637-649.	1.5	10
142	Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1761.	1.7	8
143	Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome. <i>Cells</i> , 2020, 9, 1631.	1.8	26
144	Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene. <i>PLoS ONE</i> , 2020, 15, e0235766.	1.1	2
145	Homologous recombination deficiency in epithelial ovarian cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 367-370.	0.3	2
146	Homologous recombination deficiency in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 375-379.	0.3	2
147	Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 954.	1.3	8
148	The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 151.	0.8	14
149	Cul4B promotes the progression of ovarian cancer by upregulating the expression of CDK2 and CyclinD1. <i>Journal of Ovarian Research</i> , 2020, 13, 76.	1.3	22
150	PARP and PARC inhibitors in cancer treatment. <i>Genes and Development</i> , 2020, 34, 360-394.	2.7	360
151	PARP inhibitors: a tsunami of indications in different malignancies. <i>Pharmacogenomics</i> , 2020, 21, 221-230.	0.6	16
152	A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity. <i>Nature Communications</i> , 2020, 11, 822.	5.8	62
154	PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?. <i>Current Oncology Reports</i> , 2020, 22, 29.	1.8	14
155	ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 679-686.	0.9	3

#	ARTICLE	IF	CITATIONS
156	Clinical significance of primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery in advanced ovarian cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 379-386.	0.6	23
157	First-line PARP inhibition in ovarian cancer – standard of care for all?. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 136-137.	12.5	25
158	A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 157, 214-221.	0.6	2
159	Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1222-1245.	0.8	202
160	BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis. <i>Targeted Oncology</i> , 2020, 15, 37-46.	1.7	6
161	Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment. <i>Gynecologic Oncology</i> , 2020, 156, 561-567.	0.6	21
162	Aberrant sialylation in ovarian cancers. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 337-344.	0.6	42
163	Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer. <i>Drug Discovery Today</i> , 2020, 25, 1232-1238.	3.2	28
164	Targeting tumor microenvironment in ovarian cancer: Premise and promise. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188361.	3.3	105
165	Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations. <i>Surgical Oncology</i> , 2020, 34, 40-45.	0.8	4
166	Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 903-915.	1.2	52
167	Ovarian cancer treatment is evolving: more choices, more chances. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 726-727.	1.2	0
168	PARP Inhibitors in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 1572-1575.	18.9	9
169	Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 699-709.	5.1	104
170	Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 222-231.	0.7	8
171	Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer. <i>Cancer Cell International</i> , 2020, 20, 128.	1.8	14
172	Gastrointestinal events with PARP inhibitors in cancer patients: A meta-analysis of phase II/III randomized controlled trials. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 241-255.	0.7	10
173	Clinical impact of BRCA2 mRNA expression in high-grade serous ovarian cancer: validation using the TCGA cohort. <i>Acta Oncologica</i> , 2021, 60, 187-190.	0.8	0

#	ARTICLE	IF	CITATIONS
174	Progress in systemic therapy for triple-negative breast cancer. <i>Frontiers of Medicine</i> , 2021, 15, 1-10.	1.5	16
175	PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 485-493.	1.1	23
176	Phase 1 Study of Low-Dose Fractionated Whole Abdominal Radiation Therapy in Combination With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer (GCGS-01). <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 701-711.	0.4	5
177	The current landscape of molecular profiling in the treatment of epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 333-345.	0.6	40
178	Impact of BRCA1/2 Mutations on the Efficacy of Secondary Cytoreductive Surgery. <i>Annals of Surgical Oncology</i> , 2021, 28, 3637-3645.	0.7	8
179	Palliative Radiation Therapy for Metastatic, Persistent, or Recurrent Epithelial Ovarian Cancer: Efficacy in the Era of Modern Technology and Targeted Agents. <i>Advances in Radiation Oncology</i> , 2021, 6, 100624.	0.6	5
180	Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103145.	2.0	34
181	Current Ovarian Cancer Maintenance Strategies and Promising New Developments. <i>Journal of Cancer</i> , 2021, 12, 38-53.	1.2	36
182	SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. <i>Cancer</i> , 2021, 127, 1301-1310.	2.0	20
183	Asian perspective on debulking surgery for advanced ovarian cancer: An E-survey. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1111-1116.	0.5	3
184	Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2021, 107, 100-109.	0.6	8
185	Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 302-311.	0.6	25
186	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. <i>American Journal of Transplantation</i> , 2021, 21, 460-474.	2.6	67
188	Novel agents to target treatment resistance in ovarian cancer. , 2021, , 129-149.		0
189	Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e82.	1.0	6
190	Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 103-110.	1.9	9
191	Assessing Genetic Variants in Matched Biocompartments From Patients With Serous Ovarian Cancer. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110279.	0.8	1
192	SEOM clinical guideline in ovarian cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 961-968.	1.2	22

#	ARTICLE	IF	CITATIONS
193	Major clinical research advances in gynecologic cancer in 2020. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e53.	1.0	19
194	Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in <i>TP53</i> and <i>BRCA1</i> -Deficient Cells. <i>Cancer Research</i> , 2021, 81, 2774-2787.	0.4	17
195	Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 571-584.	0.7	26
197	Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with <i>BRCA</i> -mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e27.	1.0	6
199	How to start niraparib in real-world Asian ovarian cancer patients?. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e36.	1.0	0
200	Comprehensive Genomic Profiling-Guided Niraparib Treatment of Triple-Negative Breast Cancer in a Patient With Extensive Brain Metastasis: Case Report and Literature Review. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 16-20.	0.6	1
201	Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e16.	1.0	8
202	<i>BRCA</i> Mutations and PARP Inhibitors in Breast and/or Ovarian Cancer Patients. <i>International Journal of Pharmaceutical Research and Allied Sciences</i> , 2021, 10, 33-49.	0.1	1
203	Comparisons of survival outcomes between bevacizumab and olaparib in <i>BRCA</i> -mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052). <i>Journal of Gynecologic Oncology</i> , 2021, 32, e90.	1.0	2
204	Precision Medicine in Cancer. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2021, , 433-466.	0.1	0
205	Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110496.	1.4	12
206	Epithelial ovarian cancer: Genomic landscape and evolving precision treatment. , 2021, , 1-23.		0
207	<i>CAMK2N1/RUNX3</i> methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients. <i>Clinical Epigenetics</i> , 2021, 13, 15.	1.8	10
208	<i>PARP</i> inhibitors in ovarian cancer: An overview of the practice-changing trials. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 385-397.	1.5	51
209	Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet</i> , The, 2021, 397, 281-292.	6.3	125
210	The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 693-699.	0.6	4
211	The Knowledge and Attitude of Patients Diagnosed with Epithelial Ovarian Cancer towards Genetic Testing. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2312.	1.2	2
212	Homologous recombination repair deficiency (HRD): From biology to clinical exploitation. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 299-302.	1.5	16

#	ARTICLE	IF	CITATIONS
213	Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?. <i>Seminars in Cancer Biology</i> , 2021, 77, 67-82.	4.3	12
214	Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. <i>Lancet Haematology</i> , 2021, 8, e122-e134.	2.2	139
215	Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. <i>Cancers</i> , 2021, 13, 946.	1.7	31
216	Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 149.	1.1	16
217	Molecular Signatures of Gynecological Cancers: Clinicians Perspective. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 103-110.	0.3	1
218	Targeting Nrf2 may reverse the drug resistance in ovarian cancer. <i>Cancer Cell International</i> , 2021, 21, 116.	1.8	25
219	Molecular Imaging: PARP-1 and Beyond. <i>Journal of Nuclear Medicine</i> , 2021, 62, 765-770.	2.8	11
220	Clinical considerations for the management of androgen indifferent prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 623-637.	2.0	30
221	Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 191-226.	2.3	356
222	Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II/III randomized controlled trials. <i>Journal of Chemotherapy</i> , 2021, 33, 452-461.	0.7	5
223	Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation. <i>Cancers</i> , 2021, 13, 1004.	1.7	28
224	PARPi after PARPi in epithelial ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2021, 35, 100699.	0.3	10
225	Classification of serous ovarian carcinoma based on immunogenomic profiling. <i>International Immunopharmacology</i> , 2021, 91, 107274.	1.7	3
226	Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 573801.	1.3	9
227	Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 267-276.	5.1	79
228	Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining. <i>Cancer Research</i> , 2021, 81, 3333-3346.	0.4	16
229	Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103209.	2.0	11
230	Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. <i>Molecular Cancer</i> , 2021, 20, 27.	7.9	54

#	ARTICLE	IF	CITATIONS
231	Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom. <i>Diagnostics</i> , 2021, 11, 547.	1.3	2
232	Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors. <i>Cancers</i> , 2021, 13, 1298.	1.7	24
233	BRCA1/2 mutations and survival of high-grade endometrioid endometrial cancer. <i>Gynecology and Obstetrics Clinical Medicine</i> , 2021, 1, 19-24.	0.2	0
234	Structural Variants at the <i>BRCA1/2</i> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3201-3214.	3.2	27
235	Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 116.	3.5	23
236	C�ncer de ovario. <i>Medicine</i> , 2021, 13, 1518-1526.	0.0	0
237	PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival. <i>Aging</i> , 2021, 13, 8975-8988.	1.4	13
238	Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 510-510.	0.7	13
239	Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 475-480.	1.1	3
240	Improving The Quality of Care for Persons With Advanced Epithelial Ovarian Cancer. <i>Oncology Issues</i> , 2021, 36, 36-48.	0.0	1
242	Tumor Immunometabolism Characterization in Ovarian Cancer With Prognostic and Therapeutic Implications. <i>Frontiers in Oncology</i> , 2021, 11, 622752.	1.3	9
243	An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma. <i>Current Oncology</i> , 2021, 28, 1114-1124.	0.9	4
244	Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 543-554.	1.9	13
245	ARRDC3 as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer Based on Data Mining. <i>International Journal of General Medicine</i> , 2021, Volume 14, 967-981.	0.8	5
247	The impact of opportunistic salpingectomy on ovarian cancer mortality and healthcare costs: a call for universal insurance coverage. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 397.e1-397.e6.	0.7	15
248	Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays. <i>British Journal of Cancer</i> , 2021, 125, 7-14.	2.9	14
249	Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. <i>Drug Resistance Updates</i> , 2021, 55, 100744.	6.5	43
250	Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma. <i>Cancers</i> , 2021, 13, 1875.	1.7	16

#	ARTICLE	IF	CITATIONS
251	ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids. <i>Cancers</i> , 2021, 13, 2039.	1.7	17
252	Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality. <i>Scientific Reports</i> , 2021, 11, 8856.	1.6	10
253	Assessing Preclinical Research Models for Immunotherapy for Gynecologic Malignancies. <i>Cancers</i> , 2021, 13, 1694.	1.7	1
254	Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer. <i>Molecular Oncology</i> , 2021, 15, 3626-3638.	2.1	7
255	Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review. <i>Cancers</i> , 2021, 13, 2067.	1.7	7
256	PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience. <i>JCO Global Oncology</i> , 2021, 7, 506-511.	0.8	10
257	First-Line PARP Inhibitors—Emerging Side Effects Require Caution: A Case of PARPi-Induced Pneumonitis. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 171-174.	0.6	4
258	Medical treatment of patients with gynecologic cancer during the COVID-19 pandemic. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1154-1158.	1.2	3
260	Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4791.	1.8	4
261	The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker. <i>Molecular Oncology</i> , 2021, 15, 2491-2503.	2.1	5
262	Report from the European Society of Gynaecological Oncology (ESGO) 2020 State-of-the-Art Virtual Meeting. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 658-669.	1.2	5
263	Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. <i>ESMO Open</i> , 2021, 6, 100040.	2.0	19
264	First line ovarian cancer treatment: Scanning the horizon. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103297.	2.0	0
265	Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4203.	1.8	49
266	Biomarker Jeopardy. <i>Journal of the Advanced Practitioner in Oncology</i> , 2021, 12, 285-288.	0.2	0
268	Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial. <i>Annals of Oncology</i> , 2021, 32, 512-521.	0.6	93
269	Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib. <i>Annals of Translational Medicine</i> , 2021, 9, 869-869.	0.7	6
270	NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 11125.	1.6	16

#	ARTICLE	IF	CITATIONS
271	Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer. <i>Medicina (Lithuania)</i> , 2021, 57, 501.	0.8	5
272	Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 632-642.	5.1	40
273	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , 2021, 12, 2487.	5.8	116
274	BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art. <i>Cancers</i> , 2021, 13, 2562.	1.7	13
275	Management of advanced ovarian cancer in Spain: an expert Delphi consensus. <i>Journal of Ovarian Research</i> , 2021, 14, 72.	1.3	2
276	MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer. <i>Genes</i> , 2021, 12, 742.	1.0	6
277	EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. <i>Pharmacological Research</i> , 2021, 167, 105583.	3.1	78
280	Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. <i>Gynecologic Oncology</i> , 2021, 161, 512-515.	0.6	4
281	The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value. <i>Gynecologic Oncology</i> , 2021, 161, 491-495.	0.6	2
282	Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2020-002343.	1.2	4
283	Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women. <i>Gynecologic Oncology</i> , 2021, 161, 545-552.	0.6	8
284	Present and Future for PARP Inhibitors in Ovarian Cancer. <i>Advances in Oncology</i> , 2021, 1, 139-154.	0.1	0
285	Poly (adenosine diphosphate [ADP]â€“ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 285-296.	0.8	10
286	FLABRA, frontline approach for <i>BRCA</i> testing in an ovarian cancer population: aÂLatin America epidemiologic study. <i>Future Oncology</i> , 2021, 17, 1601-1609.	1.1	2
287	Precision medicine for hereditary tumors in gynecologicâ€“malignancies. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 2597-2606.	0.6	11
288	The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China. <i>Journal of Ovarian Research</i> , 2021, 14, 68.	1.3	6
289	Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology</i> , 2021, 160, 2119-2132.e9.	0.6	83
290	Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review. <i>European Journal of Cancer</i> , 2021, 149, 49-60.	1.3	1

#	ARTICLE	IF	CITATIONS
291	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 149, 134-152.	1.3	41
292	Frequentist rules for regulatory approval of subgroups in phase III trials: A fresh look at an old problem. <i>Statistical Methods in Medical Research</i> , 2021, 30, 1725-1743.	0.7	1
293	PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data. <i>Oral Oncology</i> , 2021, 117, 105292.	0.8	21
294	Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1-23.	0.9	3
295	The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?. <i>ESMO Open</i> , 2021, 6, 100144.	2.0	77
296	Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices. <i>ESMO Open</i> , 2021, 6, 100135.	2.0	9
297	Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. <i>Gynecologic Oncology</i> , 2021, 161, 653-659.	0.6	26
298	PARP inhibitor associated treatment related myeloid neoplasms: What was a "Rare" complication may be less so. <i>Gynecologic Oncology</i> , 2021, 161, 639-641.	0.6	3
299	An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers. <i>Cancers</i> , 2021, 13, 3113.	1.7	0
300	The impact of body composition on treatment in ovarian cancer: a current insight. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1065-1074.	1.3	11
301	The systemic treatment of recurrent ovarian cancer revisited. <i>Annals of Oncology</i> , 2021, 32, 710-725.	0.6	61
302	The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks. <i>Cancers</i> , 2021, 13, 2994.	1.7	23
303	A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review). <i>International Journal of Oncology</i> , 2021, 59, .	1.4	66
304	Gemogenovatucl-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 676-680.	0.6	22
305	Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer. <i>Current Drug Targets</i> , 2022, 23, 145-155.	1.0	5
306	Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 518.	1.1	8
307	Frontline Maintenance Treatment for Ovarian Cancer. <i>Current Oncology Reports</i> , 2021, 23, 97.	1.8	3
308	Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology. <i>Npj Precision Oncology</i> , 2021, 5, 58.	2.3	5

#	ARTICLE	IF	CITATIONS
309	Biomarkers for Homologous Recombination Deficiency in Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 612.	1.1	38
310	Association of Copy Number Variation Signature and Survival in Patients With Serous Ovarian Cancer. <i>JAMA Network Open</i> , 2021, 4, e2114162.	2.8	18
312	Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103336.	2.0	3
313	Ovarian Cancer Immunotherapy and Personalized Medicine. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6532.	1.8	128
314	Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1542-1549.	1.9	10
315	Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology. <i>Biomedicines</i> , 2021, 9, 632.	1.4	30
316	PARP inhibitors and immunotherapy in ovarian and endometrial cancers. <i>British Journal of Radiology</i> , 2021, 94, 20210002.	1.0	4
317	Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes. <i>Frontiers in Immunology</i> , 2021, 12, 690201.	2.2	28
318	Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer. <i>Future Oncology</i> , 2021, 17, 2291-2304.	1.1	2
319	Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. <i>Annals of Oncology</i> , 2021, 32, 757-765.	0.6	105
320	Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). <i>Journal of Clinical Oncology</i> , 2021, 39, 1842-1855.	0.8	183
321	Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 50-56.	0.6	1
322	Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 68.e1-68.e11.	0.7	10
323	Multimodal Treatment of Primary Advanced Ovarian Cancer. <i>Anticancer Research</i> , 2021, 41, 3253-3260.	0.5	14
324	DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 254.	7.1	239
325	Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence. <i>Frontiers in Oncology</i> , 2021, 11, 697952.	1.3	2
326	Understanding and overcoming resistance to PARP inhibitors in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 773-791.	12.5	198
327	The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation. <i>Gynecologic Oncology</i> , 2021, 162, 203-209.	0.6	4

#	ARTICLE	IF	CITATIONS
328	Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1825-1837.	0.9	11
329	The Future of Parallel Tumor and Germline Genetic Testing: Is There a Role for All Patients With Cancer?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 871-878.	2.3	10
330	Tumor Treating Fields for Ovarian Carcinoma: A Modeling Study. <i>Advances in Radiation Oncology</i> , 2021, 6, 100716.	0.6	4
331	Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7884.	1.8	8
332	Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. <i>Cell Reports</i> , 2021, 36, 109412.	2.9	60
333	Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database. <i>Gynecologic Oncology</i> , 2021, 163, 64-71.	0.6	3
334	Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 825-836.	1.1	8
335	Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes. <i>Genes</i> , 2021, 12, 1103.	1.0	10
336	Efficacy and Mechanism of Buxue Yimu Pills on Gynecological Anemia: A Combination of Clinical and Network Pharmacology Study. <i>Chinese Journal of Integrative Medicine</i> , 2022, 28, 1072-1080.	0.7	7
337	Opportunistic Salpingectomy at Time of Nongynecologic Elective Procedures Could Reduce Ovarian Cancer-Related Costs and Mortality. <i>Journal of Gynecologic Surgery</i> , 2022, 38, 43-48.	0.0	2
338	GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. <i>Clinical Cancer Research</i> , 2021, 27, 5536-5545.	3.2	15
339	Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2021, 81, 4709-4722.	0.4	42
340	Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. <i>Gynecologic Oncology</i> , 2021, 163, 41-49.	0.6	17
341	Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer. <i>JAMA Oncology</i> , 2021, 7, 1231.	3.4	34
342	Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1348-1355.	1.2	3
343	High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment. <i>Cell Reports</i> , 2021, 36, 109632.	2.9	26
344	Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 975-983.	1.9	7
345	Post-chemotherapy maintenance treatment by nicotinamide riboside, a poly ADP ribose polymerase 1 inhibitor, in BRCA mutated advanced ovarian cancer – A perspective. <i>International Journal of Molecular and Immuno Oncology</i> , 0, 6, 118-121.	0.0	1

#	ARTICLE	IF	CITATIONS
346	Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 3199-3206.	0.8	5
347	The role of molecular tests for adjuvant and post-surgical treatment in gynaecological cancers. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2021, 78, 14-14.	1.4	0
348	Comparative Assessment of Diagnostic Homologous Recombination Deficiency-associated Mutational Signatures in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5681-5687.	3.2	18
349	Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. <i>Gynecologic Oncology</i> , 2021, 162, 375-381.	0.6	7
350	Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. <i>Vaccines</i> , 2021, 9, 894.	2.1	9
351	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1403-1414.	0.5	26
352	Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase III trial (ROLANDO study). <i>ESMO Open</i> , 2021, 6, 100212.	2.0	15
353	Cytotoxic and targeted therapy for BRCA1/2-driven cancers. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 36.	0.6	11
354	Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations). <i>JCO Precision Oncology</i> , 2021, 5, 1432-1442.	1.5	29
355	Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 1536.	3.4	28
356	The role of immunotherapy in the management of metastatic/recurrent female reproductive system neoplasms. <i>Meditinskiy Sovet</i> , 2021, , 76-86.	0.1	0
357	Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress. <i>Cancers</i> , 2021, 13, 4405.	1.7	8
358	Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials. <i>Annals of Translational Medicine</i> , 2021, 9, 1229-1229.	0.7	10
359	A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA. <i>Acta Clinica Belgica</i> , 2021, , 1-13.	0.5	4
360	An urgent call to raise the bar in oncology. <i>British Journal of Cancer</i> , 2021, 125, 1477-1485.	2.9	34
361	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	0.8	83
362	The evolving role of PARP inhibitors in advanced ovarian cancer. <i>Forum of Clinical Oncology</i> , 2021, 12, 82-104.	0.1	0
363	Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018. <i>Future Oncology</i> , 2021, 17, 4263-4274.	1.1	3

#	ARTICLE	IF	CITATIONS
364	Research progress on the association between environmental pollutants and the resistance mechanism of PARP inhibitors in ovarian cancer. <i>Environmental Science and Pollution Research</i> , 2021, 28, 49491-49506.	2.7	0
366	Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. <i>Gynecologic Oncology</i> , 2021, 162, 482-495.	0.6	31
367	PARP inhibitor maintenance for primary ovarian cancer – A missed opportunity for precision medicine. <i>Gynecologic Oncology</i> , 2021, 163, 11-13.	0.6	7
368	An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions. <i>Oncology and Therapy</i> , 2021, 9, 347-364.	1.0	10
369	Total parietal peritonectomy performed during interval cytoreductive surgery for advanced epithelial serous ovarian cancer results in a low incidence of platinum resistant recurrence – results of a prospective multi-centre study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2150-2157.	0.5	5
370	Development of MRI-Based Radiomics Model to Predict the Risk of Recurrence in Patients With Advanced High-Grade Serous Ovarian Carcinoma. <i>American Journal of Roentgenology</i> , 2021, 217, 664-675.	1.0	18
371	Let-7i Reduces Aggressive Phenotype and Induces BRCAness in Ovarian Cancer Cells. <i>Cancers</i> , 2021, 13, 4617.	1.7	4
372	Role of adjuvant and post-surgical treatment in gynaecological cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 78, 2-13.	1.4	9
373	Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor. <i>Frontiers in Oncology</i> , 2021, 11, 724620.	1.3	3
374	Determinants of Homologous Recombination Deficiency in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 4716.	1.7	9
375	Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers. <i>Gynecologic Oncology</i> , 2021, 163, 220-228.	0.6	4
376	Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 754094.	1.3	5
377	ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA – MONO) and rucaparib in combination with nivolumab (ATHENA – COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1589-1594.	1.2	40
378	Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review. <i>Anticancer Research</i> , 2021, 41, 4673-4685.	0.5	8
379	Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human. <i>Cancers</i> , 2021, 13, 4553.	1.7	6
380	Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. <i>Cancer Medicine</i> , 2021, 10, 7162-7173.	1.3	4
381	Predicting cancer drug TARGETS - Treatment Response Generalized Elastic-net Signatures. <i>Npj Genomic Medicine</i> , 2021, 6, 76.	1.7	10
382	Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation – real life data. <i>Gynecologic Oncology</i> , 2021, 163, 569-577.	0.6	7

#	ARTICLE	IF	CITATIONS
383	Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors. <i>Cancer Treatment Reviews</i> , 2021, 101, 102298.	3.4	11
384	Ovarian Cancerâ€“Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6559-6569.	3.2	9
385	Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. <i>Clinical Cancer Research</i> , 2021, 27, 6106-6114.	3.2	9
386	Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 78, 64-73.	1.4	9
387	Synthetic Lethality in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2117-2128.	1.9	20
388	The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2021, 162, 702-706.	0.6	6
389	PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. <i>Cancer Treatment Reviews</i> , 2021, 99, 102255.	3.4	25
390	Real-world Experience of Niraparib in Newly-diagnosed Epithelial Ovarian Cancer. <i>Anticancer Research</i> , 2021, 41, 4603-4607.	0.5	0
391	Efficacy and safety of first-line veliparib and carboplatinâ€“paclitaxel in patients with HER2â€™ advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. <i>European Journal of Cancer</i> , 2021, 154, 35-45.	1.3	10
392	Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 311.	3.5	26
393	Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis. <i>Pharmacological Research</i> , 2021, 172, 105808.	3.1	20
394	Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2021, 32, 1300-1303.	0.6	41
395	Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1377-1387.	0.5	0
396	The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas. <i>Cancer Treatment Reviews</i> , 2021, 100, 102294.	3.4	21
397	Malignant diseases of the ovary, fallopian tube, and peritoneum. , 2022, , 707-753.e7.		2
398	Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature. <i>Diagnostics</i> , 2021, 11, 199.	1.3	24
399	Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e21.	1.0	7
400	DNA Damage Response. , 2021, , 1-12.		0

#	ARTICLE	IF	CITATIONS
401	Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease. <i>Cancer Biology and Therapy</i> , 2021, 22, 89-105.	1.5	15
402	MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer. <i>Diagnostics</i> , 2021, 11, 84.	1.3	15
403	Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States. <i>JAMA Network Open</i> , 2020, 3, e2028620.	2.8	18
404	PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102973.	2.0	31
405	PARP inhibition in the ovarian cancer patient: Current approvals and future directions. , 2020, 213, 107588.		7
406	Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 418-425.	0.6	7
407	Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials. <i>Bioscience Reports</i> , 2020, 40, .	1.1	13
408	Nephrotoxicity Associated With Niraparib. <i>American Journal of Kidney Diseases</i> , 2020, 76, 898-900.	2.1	8
409	Concordance Between Tumor and Germline <i>BRCA</i> Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 917-923.	3.0	26
410	Making radiation therapy more effective in the era of precision medicine. <i>Precision Clinical Medicine</i> , 2020, 3, 272-283.	1.3	3
411	Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. <i>Obstetrics and Gynecology</i> , 2021, 137, 108-121.	1.2	150
412	Innovations in targeted therapies for triple negative breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2021, 33, 34-47.	0.9	4
413	Renal insufficiency in patients on PARP inhibitors: Case-based review of possible mechanisms and management. <i>Journal of Onco-Nephrology</i> , 2021, 5, 8-12.	0.3	1
414	Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series. <i>American Journal of Case Reports</i> , 2020, 21, e927008.	0.3	5
415	Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer. <i>Oncotarget</i> , 2019, 10, 6981-6996.	0.8	9
416	Current practices on genetic testing in ovarian cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 1703-1703.	0.7	7
417	Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic <i>BRCA2</i> -mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12979-12986.	1.0	7
418	Synthetic Lethal Activity of Benzophenanthridine Alkaloids From <i>Zanthoxylum coco</i> Against <i>BRCA1</i> -Deficient Cancer Cells. <i>Frontiers in Pharmacology</i> , 2020, 11, 593845.	1.6	5

#	ARTICLE	IF	CITATIONS
419	The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas. <i>Cancers</i> , 2020, 12, 2805.	1.7	30
420	Integration of PARP-inhibitors in ovarian cancer therapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, 171-182.	0.5	3
421	Major clinical research advances in gynecologic cancer in 2019. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e48.	1.0	10
422	Genetic Alterations in Ovarian Cancer as Prognostic and Predictive Biomarkers of Therapy Response and Surgical Outcomes. , 2021, , 135-166.		0
423	The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers. , 2021, , 59-133.		0
424	An Introduction to the Current Management of Ovarian Cancer in the Era of Precision Oncology. , 2021, , 19-57.		0
425	Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e95.	1.0	5
426	JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer. <i>Cancer</i> , 2022, 128, 65-74.	2.0	36
428	Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics. <i>Journal of Ovarian Research</i> , 2021, 14, 140.	1.3	8
429	Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 323.	3.5	12
431	Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 155, 61-85.	1.0	145
432	Gemogenovatumel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 459-464.	0.6	11
433	Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1369-1373.	1.2	12
434	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 246-253.	0.6	62
435	Evaluation of circulating Dickkopf-1 as a prognostic biomarker in ovarian cancer patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 109-117.	1.4	4
436	Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go Beyond. <i>Journal of Oncology</i> , 2021, 2021, 1-5.	0.6	3
437	Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction. <i>Frontiers in Oncology</i> , 2021, 11, 675972.	1.3	21
439	Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance. <i>Biomedicines</i> , 2021, 9, 1512.	1.4	29

#	ARTICLE	IF	CITATIONS
440	A DNA Damage Response Gene Panel for Different Histologic Types of Epithelial Ovarian Carcinomas and Their Outcomes. <i>Biomedicines</i> , 2021, 9, 1384.	1.4	4
441	Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders. <i>Human Cell</i> , 2022, 35, 199-213.	1.2	20
442	Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer. <i>Targeted Oncology</i> , 2021, 16, 839-845.	1.7	17
443	Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer. <i>Cancer Science</i> , 2021, 112, 5055-5067.	1.7	6
444	Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 13-27.	0.6	1
445	Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1721-1731.	5.1	172
446	Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers. <i>Genes</i> , 2021, 12, 1593.	1.0	2
447	Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study. <i>Cancers</i> , 2021, 13, 5152.	1.7	7
448	Poly(ADP-Ribose) Polymerase Inhibitors and Myeloid Neoplasm Risk—Clues to a Mechanistic Connection?. <i>JAMA Oncology</i> , 2021, 7, 1763.	3.4	0
449	Ovarian cancer—ASCO annual meeting update 2021. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 342.	0.3	1
450	Precision Oncology of High-Grade Ovarian Cancer Defined through Targeted Sequencing. <i>Cancers</i> , 2021, 13, 5240.	1.7	1
451	Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 4829.	1.0	3
452	Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients. <i>International Journal of Clinical Oncology</i> , 2022, 27, 441-447.	1.0	2
453	Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100873.	0.3	5
454	PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188633.	3.3	20
455	Molecular Testing in Ovarian Cancer: Recommendations and Treatment Considerations. , 2020, , 171-186.		0
456	Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?. , 2020, 3, 666-671.		3
458	A Brief Review on Dual Target of PARP1 and STAT3 for Cancer Therapy: A Novel Perception. <i>Current Enzyme Inhibition</i> , 2020, 16, 115-134.	0.3	1

#	ARTICLE	IF	CITATIONS
460	Optimization of Both the Diagnosis and Therapeutic Strategy Using Panel Testing for a Case of Pleural Metastasis of Sinus Carcinoma. Japanese Journal of Lung Cancer, 2020, 60, 364-370.	0.0	1
461	The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer. British Journal of Cancer, 2021, , .	2.9	3
462	Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers. Cancers, 2021, 13, 5480.	1.7	16
463	U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review. Clinical Cancer Research, 2022, 28, 1058-1071.	3.2	11
464	Homologous recombination proficiency in ovarian and breast cancer patients. BMC Cancer, 2021, 21, 1154.	1.1	35
465	Adverse events of targeted therapies approved for women's cancers. International Journal of Women's Dermatology, 2021, 7, 552-559.	1.1	0
466	Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data. Advances in Therapy, 2022, 39, 328-345.	1.3	9
467	Ovarian cancer risk assessment in the era of next-generation sequencing. Annals of Translational Medicine, 2020, 8, 1704-1704.	0.7	3
468	Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy. Current Cancer Drug Targets, 2020, 20, 853-867.	0.8	1
472	The latest first-line treatment options for ovarian cancer: focus on maintenance therapy. Meditsinskiy Sovet, 2020, , 62-68.	0.1	0
473	Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance. Current Opinion in Obstetrics and Gynecology, 2021, 33, 19-25.	0.9	8
474	Nomogram Models for Predicting Risk and Prognosis of Newly Diagnosed Ovarian Cancer Patients with Liver Metastases - A Large Population-Based Real-World Study. Journal of Cancer, 2021, 12, 7255-7265.	1.2	1
475	Maligne Tumoren des Ovars. , 2020, , 439-454.		0
476	History of Oncotherapies in Cancer Biology. , 2020, , 1-13.		1
477	Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?. Journal of Gynecologic Oncology, 2020, 31, e95.	1.0	0
478	Upfront Maintenance Poly(Adenosine Diphosphate Ribose) Polymerase Inhibitors in Ovarian Cancer: A Ray of Hope or Just a Mirage!. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 173-181.	0.1	0
479	P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib. Molecular Pharmaceutics, 2021, 18, 4371-4384.	2.3	6
480	Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts. British Journal of Cancer, 2022, 126, 120-128.	2.9	21

#	ARTICLE	IF	CITATIONS
481	BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients. <i>Current Oncology</i> , 2021, 28, 4446-4456.	0.9	2
483	Germline and Somatic <i>BRCA1/2</i> Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea. <i>Cancer Research and Treatment</i> , 2020, 52, 1229-1241.	1.3	8
485	Cancer Epigenomics and Beyond: Advancing the Precision Oncology Paradigm. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 147-156.	0.6	0
486	mTOR inhibition overcomes primary and acquired resistance to Wee1 inhibition by augmenting replication stress in epithelial ovarian cancers. <i>American Journal of Cancer Research</i> , 2020, 10, 908-924.	1.4	3
487	Treatment algorithm in patients with ovarian cancer. <i>Facts, Views & Vision in ObGyn</i> , 2020, 12, 227-239.	0.5	2
488	The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target. <i>American Journal of Clinical and Experimental Urology</i> , 2021, 9, 73-87.	0.4	4
489	Effects of PICCO in the guidance of goal-directed fluid therapy for gastrointestinal function after cytoreductive surgery for ovarian cancer. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 4852-4859.	0.0	0
490	PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review. <i>Advances in Genetics</i> , 2021, 108, 35-80.	0.8	5
492	Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy. <i>Current Oncology Reports</i> , 2021, 23, 148.	1.8	7
493	DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma. <i>PLoS Computational Biology</i> , 2021, 17, e1009562.	1.5	6
495	Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?. <i>Cancers</i> , 2021, 13, 5756.	1.7	11
496	A folic acid-modified non-viral vector combines gene therapy with chemotherapy to reverse cancer chemotherapy resistance. <i>Applied Materials Today</i> , 2022, 26, 101277.	2.3	4
497	Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations. <i>Frontiers in Pharmacology</i> , 2021, 12, 743073.	1.6	10
498	BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report. <i>Genes</i> , 2021, 12, 1917.	1.0	2
499	Breast cancer surveillance following ovarian cancer in BRCA mutation carriers. <i>Gynecologic Oncology</i> , 2022, 164, 202-207.	0.6	3
500	Response to and toxicity of weekly paclitaxel and carboplatin in patients with stage III&IV ovarian cancer and poor general condition. <i>Molecular and Clinical Oncology</i> , 2021, 16, 14.	0.4	1
501	Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	2
502	Machine Learning for Recurrence Prediction of Gynecologic Cancers Using Lynch Syndrome-Related Screening Markers. <i>Cancers</i> , 2021, 13, 5670.	1.7	7

#	ARTICLE	IF	CITATIONS
503	Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 164, 27-33.	0.6	3
505	Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer. <i>Cancers</i> , 2021, 13, 5899.	1.7	9
506	B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression. <i>Cancer Immunology Research</i> , 2022, 10, 56-69.	1.6	49
507	Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 762741.	1.6	6
508	Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy. <i>Cancer Gene Therapy</i> , 2022, 29, 993-1000.	2.2	4
510	Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2123-2131.	13.9	144
511	Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors. <i>Molecular Oncology</i> , 2022, 16, 1591-1607.	2.1	7
512	European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. <i>Annals of Oncology</i> , 2022, 33, 276-287.	0.6	68
514	DNA Damage Response. , 2021, , 536-547.		0
516	Randomized Phase 3 Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor Positive Ovarian Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
517	Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine. <i>JCO Precision Oncology</i> , 2022, 6, e2000508.	1.5	7
518	Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China. <i>Frontiers in Oncology</i> , 2021, 11, 746571.	1.3	10
519	Ovarian cancer and KiSS-1 gene expression: A consideration of the use of Kisspeptin plus Kisspeptin aptamers in diagnostics and therapy. <i>European Journal of Pharmacology</i> , 2022, 917, 174752.	1.7	2
520	Homologous recombination deficiency testing in first-line ovarian cancer. <i>Annals of Oncology</i> , 2022, 33, 231-233.	0.6	1
522	Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: Advances, challenges, and opportunities. <i>European Journal of Medicinal Chemistry</i> , 2022, 230, 114094.	2.6	18
523	Synergistic Effect of PARP Inhibitor and BRD4 Inhibitor in Multiple Models of Ovarian Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
524	Use of PARP Inhibitors for Ovarian Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 636-638.	2.3	1
525	Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 432-440.	1.0	5

#	ARTICLE	IF	CITATIONS
526	PARP Inhibitors in Pancreatic Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 465-475.	1.0	18
527	Beyond BRCA1/2: Homologous Recombination Repair Genetic Profile in a Large Cohort of Apulian Ovarian Cancers. <i>Cancers</i> , 2022, 14, 365.	1.7	5
528	A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer. <i>BMC Cancer</i> , 2022, 22, 28.	1.1	10
529	PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. <i>Cancers</i> , 2022, 14, 599.	1.7	8
530	Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma. <i>BMC Cancer</i> , 2022, 22, 59.	1.1	3
531	Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis. <i>Current Oncology</i> , 2022, 29, 321-336.	0.9	5
532	Homologous Recombination Deficiency: Concepts, Definitions, and Assays. <i>Oncologist</i> , 2022, 27, 167-174.	1.9	69
533	The Development of ¹⁸ F Fluorothantrate: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1. <i>Radiology Imaging Cancer</i> , 2022, 4, e210070.	0.7	3
534	A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	6
535	Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis. <i>Gynecologic Oncology</i> , 2022, 164, 498-504.	0.6	24
536	PARP mediated DNA damage response, genomic stability and immune responses. <i>International Journal of Cancer</i> , 2022, 150, 1745-1759.	2.3	18
537	Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901). <i>Oncologist</i> , 2022, 27, e116-e125.	1.9	6
538	Oleanolic Acid (OA) Targeting UNC5B Inhibits Proliferation and EMT of Ovarian Cancer Cell and Increases Chemotherapy Sensitivity of Niraparib. <i>Journal of Oncology</i> , 2022, 2022, 1-12.	0.6	2
539	Mainstreaming Genetic Testing for Epithelial Ovarian Cancer by Oncology Providers: A Survey of Current Practice. <i>JCO Precision Oncology</i> , 2022, 6, e2100409.	1.5	5
540	Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial. <i>Gynecologic Oncology</i> , 2022, 164, 278-287.	0.6	6
541	Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. <i>Gynecologic Oncology</i> , 2022, 164, 245-253.	0.6	15
542	Testing for homologous recombination deficiency – does it provide new insights for the use of veliparib?. <i>Gynecologic Oncology</i> , 2022, 164, 243-244.	0.6	0
543	Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. <i>Gynecologic Oncology</i> , 2022, 164, 254-264.	0.6	51

#	ARTICLE	IF	CITATIONS
544	BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 345-355.	0.8	23
545	Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology. <i>Cancer Treatment Reviews</i> , 2022, 104, 102337.	3.4	6
546	Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100939.	0.3	7
547	The Changing Landscape of Gynecologic Cancer Mortality in the United States. <i>Obstetrics and Gynecology</i> , 2022, 139, 440-442.	1.2	43
548	Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study. <i>Gynecologic Oncology</i> , 2022, 165, 97-104.	0.6	8
549	The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 555-567.	1.9	11
550	Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2. <i>Cells</i> , 2022, 11, 539.	1.8	17
551	Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy. <i>Frontiers in Immunology</i> , 2022, 13, 826577.	2.2	3
552	Perspectives on PARP Inhibitor Combinations for Ovarian Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 754524.	1.3	7
553	Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103539.	2.0	11
554	The Use of Targeted Agents in the Treatment of Gynecologic Cancers. <i>Current Treatment Options in Oncology</i> , 2022, 23, 15-28.	1.3	3
555	Current and Emerging Therapies for Neuroendocrine Prostate Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
556	PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	18
557	The BRCA Gene in Epithelial Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1235.	1.7	9
558	Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements. <i>Cells</i> , 2022, 11, 650.	1.8	34
559	Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. <i>Trends in Cancer</i> , 2022, 8, 426-444.	3.8	13
560	The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 1417-1429.	0.8	3
561	Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations. <i>Cancers</i> , 2022, 14, 1132.	1.7	8

#	ARTICLE	IF	CITATIONS
562	RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 185-199.	1.5	16
563	Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives. <i>Frontiers in Oncology</i> , 2022, 12, 831612.	1.3	5
564	The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer. <i>Annals of Oncology</i> , 2022, 33, 593-601.	0.6	10
565	Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review. <i>Cancers</i> , 2022, 14, 1180.	1.7	8
566	PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. <i>Cancers</i> , 2022, 14, 1003.	1.7	18
567	Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents. <i>Cancers</i> , 2022, 14, 953.	1.7	16
568	Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. <i>The Cochrane Library</i> , 2022, 2022, CD007929.	1.5	22
569	Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers. <i>Cancers</i> , 2022, 14, 1122.	1.7	5
571	Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy. <i>Current Cancer Drug Targets</i> , 2022, 22, 530-536.	0.8	4
573	Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. <i>Cancers</i> , 2022, 14, 1189.	1.7	3
574	Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer. <i>The Cochrane Library</i> , 2022, 2022, CD012007.	1.5	5
575	Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives. <i>Cancers</i> , 2022, 14, 1098.	1.7	8
576	Core Homologous Recombination Mutations and Improved Survival in Nonpancreatic GI Cancers. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 137-141.	0.6	0
577	An update on the safety of olaparib for treating ovarian cancer. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 447-451.	1.0	2
578	Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers. <i>Current Oncology Reports</i> , 2022, 24, 889-904.	1.8	3
579	The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3871.	1.8	14
580	Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3238.	1.8	14
581	Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future—Five-Years' Single-Institution Experience of 762 Consecutive Patients. <i>Cancers</i> , 2022, 14, 1638.	1.7	3

#	ARTICLE	IF	CITATIONS
582	BRCA1/2 in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?. <i>British Journal of Cancer</i> , 2022, 127, 163-167.	2.9	2
583	Multi-Disciplinary Care Planning of Ovarian Cancer in Older Patients: General Statement – A Position Paper from SOFOG-GINECO-FRANCOGYN-SFPO. <i>Cancers</i> , 2022, 14, 1295.	1.7	4
584	Germline Pathogenic Variants in <i>BRCA1</i> and <i>BRCA2</i> : Malignancies Beyond Female Breast and Ovarian Cancers. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200003.	0.8	0
585	Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 799-803.	1.2	2
586	Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research. <i>Frontiers in Oncology</i> , 2022, 12, 837233.	1.3	2
587	Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study. <i>Frontiers in Oncology</i> , 2022, 12, 852772.	1.3	7
588	DNA repair defects in cancer and therapeutic opportunities. <i>Genes and Development</i> , 2022, 36, 278-293.	2.7	45
589	Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis. <i>BMC Cancer</i> , 2022, 22, 346.	1.1	4
590	Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models. <i>Frontiers in Oncology</i> , 2022, 12, 862321.	1.3	1
591	Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS. <i>Frontiers in Pharmacology</i> , 2022, 13, 851246.	1.6	15
592	Genetic diagnosis of pseudomyxoma peritonei originating from mucinous borderline tumor inside an ovarian teratoma. <i>BMC Medical Genomics</i> , 2022, 15, 51.	0.7	1
593	Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery. <i>Gynecologic Oncology</i> , 2022, , .	0.6	2
594	Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1285.	1.7	3
595	PARP Inhibitors Resistance: Mechanisms and Perspectives. <i>Cancers</i> , 2022, 14, 1420.	1.7	22
596	Silencing of FANCI Promotes DNA Damage and Sensitizes Ovarian Cancer Cells to Carboplatin. <i>Current Cancer Drug Targets</i> , 2022, 22, 591-602.	0.8	4
597	PARP inhibition in breast cancer: progress made and future hopes. <i>Npj Breast Cancer</i> , 2022, 8, 47.	2.3	42
598	The STING pathway: Therapeutic vulnerabilities in ovarian cancer. <i>British Journal of Cancer</i> , 2022, 127, 603-611.	2.9	6
599	Trends in the Incidence and Survival Rates of Primary Ovarian Clear Cell Carcinoma Compared to Ovarian Serous Carcinoma in Korea. <i>Frontiers in Oncology</i> , 2022, 12, 874037.	1.3	4

#	ARTICLE	IF	CITATIONS
600	Templated Insertions Are Associated Specifically with <i>BRCA2</i> Deficiency and Overall Survival in Advanced Ovarian Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1061-1070.	1.5	1
601	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2022, 40, 1231-1258.	0.8	96
602	Rucaparib for <i>BRCA1/2</i> -mutated pretreated ovarian cancer: reflections from the ARIEL4 trial. <i>Lancet Oncology</i> , The, 2022, 23, 440-441.	5.1	1
603	Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center. <i>Gynecologic Oncology</i> , 2022, 165, 478-485.	0.6	3
604	Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2022, 86, 207-223.	4.3	35
605	Peritoneal restoration by repurposing vitamin D inhibits ovarian cancer dissemination via blockade of the TGF- β 1/thrombospondin-1 axis. <i>Matrix Biology</i> , 2022, 109, 70-90.	1.5	19
606	Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors. <i>European Journal of Cancer</i> , 2022, 166, 87-99.	1.3	21
607	Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 482-490.	1.0	0
608	Development of Next-Generation Poly(ADP-Ribose) Polymerase Selective Inhibitors. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 521-528.	1.0	10
609	Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 506-510.	1.0	1
610	With Our Powers Combined. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 511-520.	1.0	1
611	Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13650.	1.8	9
612	What's next for PARP inhibitors?. <i>Nature</i> , 2021, 600, S36-S38.	18.7	7
613	Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 153-158.	1.2	2
614	The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review. <i>Cancers</i> , 2022, 14, 98.	1.7	16
615	Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas. <i>Cancers</i> , 2021, 13, 6120.	1.7	2
616	Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring. <i>Cancers</i> , 2022, 14, 168.	1.7	5
617	Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape. <i>Cancers</i> , 2022, 14, 44.	1.7	16

#	ARTICLE	IF	CITATIONS
618	Treatment-induced sarcoidosis in a patient with metastatic clear cell ovarian cancer. <i>BMJ Case Reports</i> , 2021, 14, e247278.	0.2	1
619	Prise en charge chirurgicale du cancer Épithélial de l'ovaire " première ligne et première rechute. <i>Bulletin Du Cancer</i> , 2021, 108, S13-S21.	0.6	6
620	Targeting DNA repair pathway in cancer: Mechanisms and clinical application. <i>MedComm</i> , 2021, 2, 654-691.	3.1	34
621	PARP inhibitors as a radiosensitizer: a future promising approach in prostate cancer?. <i>Ecancermedalscience</i> , 2021, 15, ed118.	0.6	4
622	Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer. <i>Cells</i> , 2021, 10, 3408.	1.8	4
623	Organoids and epithelial ovarian cancer " a future tool for personalized treatment decisions?. <i>Molecular and Clinical Oncology</i> , 2021, 16, 29.	0.4	2
624	LDH-A inhibitors as remedies to enhance the anticancer effects of PARP inhibitors in ovarian cancer cells. <i>Aging</i> , 2021, 13, 25920-25930.	1.4	9
626	Traitement médical de première ligne du cancer Épithélial de l'ovaire de haut grade. <i>Bulletin Du Cancer</i> , 2021, 108, S5-S12.	0.6	3
627	Emerging role of m6A methylation modification in ovarian cancer. <i>Cancer Cell International</i> , 2021, 21, 663.	1.8	9
628	OUP accepted manuscript. <i>Japanese Journal of Clinical Oncology</i> , 2022, , .	0.6	0
629	Recent Advances in Ovarian Cancer Treatment. <i>Journal of the Nihon University Medical Association</i> , 2022, 81, 23-28.	0.0	0
630	Appropriate Selection of PARP Inhibitors in Ovarian Cancer. <i>Current Treatment Options in Oncology</i> , 2022, 23, 887-903.	1.3	17
631	Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 149-171.	0.5	3
632	PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 607-631.	1.9	20
633	Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1001-1012.	1.0	8
634	Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2568-2577.	0.8	18
635	Tumor genetics and individualized therapy. <i>Der Gynakologe</i> , 0, , .	1.0	0
636	The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2911-2922.	3.2	19

#	ARTICLE	IF	CITATIONS
637	An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 683-695.	1.1	6
638	Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	18
639	A Real World Perspective of PARP Inhibitor Use in Gynecological Cancer Patients. <i>Journal of Pharmacy Practice</i> , 2023, 36, 1134-1141.	0.5	2
640	Dual Fluorescence Isogenic Synthetic Lethal Kinase Screen and High-Content Secondary Screening for MUC16/CA125-Selective Agents. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 775-785.	1.9	0
641	Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network. <i>Cancers</i> , 2022, 14, 1965.	1.7	1
649	To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?. <i>Gynecology & Obstetrics (Sunnyvale, Calif)</i> , 2021, 11, .	0.1	0
650	The Overtreatment and Cost Effectiveness of Primary Secondary Maintenance Therapy with Poly-Adenosine Ribose Phosphate Inhibitors (PARPi) for Epithelial Ovarian Cancer (EOC).. <i>Gynecology & Obstetrics (Sunnyvale, Calif)</i> , 2021, 11, .	0.1	0
651	Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052). <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	4
653	Nephrotoxicity in cancer treatment: An update. <i>Advances in Cancer Research</i> , 2022, , 77-129.	1.9	4
654	Successful Treatment of a Patient With Brain Metastasis From Ovarian Cancer With BRCA Wild Type Using Niraparib: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2022, 12, 873198.	1.3	5
655	An appraisal of FDA approvals for adult solid tumours in 2017â€“2021: has the eagle landed?. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 486-492.	12.5	14
656	Deoxyribonucleic Acid Damage Response Defects. <i>Advances in Oncology</i> , 2022, 2, 195-211.	0.1	0
657	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3053-3065.	3.2	26
658	Combinatorial Treatment with PARP-1 Inhibitors and Cisplatin Attenuates Cervical Cancer Growth through Fos-Driven Changes in Gene Expression. <i>Molecular Cancer Research</i> , 2022, 20, 1183-1192.	1.5	7
659	Curcumol Targeting PAX8 Inhibits Ovarian Cancer Cell Migration and Invasion and Increases Chemotherapy Sensitivity of Niraparib. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	2
662	Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1115-1124.	1.9	3
663	The Landscape of Personalized Medicine in Gynecologic Cancer. <i>Advances in Oncology</i> , 2022, 2, 99-105.	0.1	1
664	Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial. <i>BMC Cancer</i> , 2022, 22, 508.	1.1	4

#	ARTICLE	IF	CITATIONS
665	Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. <i>Gynecologic Oncology</i> , 2022, 166, 36-43.	0.6	18
666	Potential clinical utility of liquid biopsies in ovarian cancer. <i>Molecular Cancer</i> , 2022, 21, 114.	7.9	51
667	Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class. <i>JAMA Oncology</i> , 2022, 8, 879.	3.4	14
668	The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis. <i>Journal of Chemotherapy</i> , 2022, , 1-8.	0.7	3
670	State of the science: Contemporary front-line treatment of advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 166, 18-24.	0.6	6
671	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. <i>Cancers</i> , 2022, 14, 2470.	1.7	4
672	Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1285-1295.	1.9	4
673	Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance. <i>Cancers</i> , 2022, 14, 2504.	1.7	12
674	Efficacy and Safety of Placebo During the Maintenance Therapy of Ovarian Cancer in Randomized Controlled Trials: A Systematic Review and Meta-analysis. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	0
675	Identification of CD8+ T Cell Related Biomarkers in Ovarian Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
676	Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions. <i>Surgical Pathology Clinics</i> , 2022, , .	0.7	0
677	Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort. <i>BMC Cancer</i> , 2022, 22, .	1.1	18
678	Is there a "low-risk" patient population in advanced epithelial ovarian cancer?: a critical analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 728-734.	0.7	3
679	Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
680	Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2022, 170, 169-178.	1.3	2
681	Ovarian cancer recurrence: "is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?" <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 451-458.	0.9	6
682	A Retrospective Analysis of Clinical Biomarkers for Olaparib Maintenance Therapy in Patients with Recurrent Ovarian Cancer. <i>Tohoku Journal of Experimental Medicine</i> , 2022, , .	0.5	1
683	Molecular analysis of ascitic fluid cytology reflects genetic changes of malignancies of the ovary equivalent to surgically resected specimens. <i>Cancer Cytopathology</i> , 2022, 130, 640-649.	1.4	5

#	ARTICLE	IF	CITATIONS
684	PARP Inhibitors Rising as an Epoch-Making Strategy in First-Line Maintenance Therapy of Ovarian Cancer: A Systematic Review and Meta-Analysis. <i>Cancer Investigation</i> , 2022, 40, 889-900.	0.6	1
685	Ovarian cancer in primary care. <i>InnovAiT</i> , 0, , 175573802211068.	0.0	0
686	Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
687	A Follow-Up Study of Ovarian Cancer (OOPS): A Study Protocol. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	15
688	VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients. <i>PLoS ONE</i> , 2022, 17, e0269680.	1.1	1
689	Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD). <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	23
690	Characterization of rare histological subtypes of ovarian cancer based on molecular profiling. <i>Cancer Medicine</i> , 0, , .	1.3	2
691	A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENAâ€œMONO/GOG-3020/ENGOT-ov45). <i>Journal of Clinical Oncology</i> , 2022, 40, 3952-3964.	0.8	125
692	PARP Inhibitors: A New Horizon for Patients with Prostate Cancer. <i>Biomedicines</i> , 2022, 10, 1416.	1.4	20
693	Postoperative Hormone Replacement Therapy and Survival in Women with Ovarian Cancer. <i>Cancers</i> , 2022, 14, 3090.	1.7	3
694	Realâ€œlife data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (<scp>RESPONSE</scp> trial). <i>Cancer</i> , 2022, 128, 3080-3089.	2.0	7
695	Circulating tumor DNA: current challenges for clinical utility. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	50
696	Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
697	OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. <i>Gynecologic Oncology</i> , 2022, 166, 219-229.	0.6	23
698	A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers. <i>Current Oncology</i> , 2022, 29, 4354-4369.	0.9	1
699	Highlights from the 2022 Society of Gynecologic Oncology Annual Meeting on Women's Cancer. <i>Gynecologic Oncology</i> , 2022, , .	0.6	2
700	Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers. <i>British Journal of Cancer</i> , 2022, 127, 1123-1132.	2.9	3
701	The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. <i>Cancers</i> , 2022, 14, 2950.	1.7	9

#	ARTICLE	IF	CITATIONS
702	Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer – International considerations amongst upper middle- and high-income countries (UMIC and HIC). <i>Gynecologic Oncology Reports</i> , 2022, 42, 101028.	0.3	5
703	Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer. <i>Journal of Clinical Pathology</i> , 2023, 76, 684-689.	1.0	0
704	Olaparib maintenance therapy after frontline chemotherapy in patients with BRCA-mutated ovarian cancer: real-world results in expanded access program. <i>Meditinskiy Sovet</i> , 2022, , 77-83.	0.1	0
705	Hyperthermia synergistically enhances antitumor efficacy of PARP inhibitor through impacting homologous recombination repair and oxidative stress in vitro. <i>Biochemical and Biophysical Research Communications</i> , 2022, 619, 49-55.	1.0	1
706	Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	4
707	The increasing importance of pathology in modern clinical trial conduct: OlympiA as a case in point. <i>Pathology</i> , 2022, , .	0.3	0
708	Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion. <i>Facts, Views & Vision in ObGyn</i> , 2022, 14, 111-120.	0.5	1
709	Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. <i>Annals of Oncology</i> , 2022, 33, 1021-1028.	0.6	50
710	Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials. <i>Journal of Market Access & Health Policy</i> , 2022, 10, .	0.8	2
711	Low BRCA1/2 germline mutation rate in a French-Canadian population with a diagnosis of epithelial tubo-ovarian carcinoma. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2022, , .	0.3	0
712	The Potential of Novel Lipid Agents for the Treatment of Chemotherapy-Resistant Human Epithelial Ovarian Cancer. <i>Cancers</i> , 2022, 14, 3318.	1.7	1
713	Impairment of RAD17 Functions by miR-506-3p as a Novel Synthetic Lethal Approach Targeting DNA Repair Pathways in Ovarian Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
714	Nestin as a Prognostic Biomarker in High-grade Epithelial Ovarian Cancer Treated by Neoadjuvant Chemotherapy. <i>Anticancer Research</i> , 2022, 42, 3583-3594.	0.5	0
715	Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis. <i>Gynecologic Oncology</i> , 2022, 166, 425-431.	0.6	12
716	Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes. <i>Cancer Science</i> , 2022, 113, 2943-2951.	1.7	11
717	Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8577.	1.2	49
718	Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations. <i>Current Opinion in Oncology</i> , 2022, 34, 559-569.	1.1	6
719	Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. , 2022, 10, e005041.		31

#	ARTICLE	IF	CITATIONS
720	Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
721	Niraparib treatment for patients with <i>BRCA</i> -mutated ovarian cancer: review of clinical data and therapeutic context. <i>Future Oncology</i> , 2022, 18, 2505-2536.	1.1	4
722	Rucaparib for recurrent ovarian cancer with <i>BRCA1</i> and <i>BRCA2</i> mutations. <i>Lancet Oncology</i> , The, 2022, 23, e314.	5.1	1
723	Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1009-1020.	5.1	44
724	Review of Toxicities of PARP Inhibitors in Metastatic Castrate Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 183-193.	0.9	6
725	Impact of disease progression on health-related quality of life of advanced ovarian cancer patients – Pooled analysis from the PRIMA trial. <i>Gynecologic Oncology</i> , 2022, 166, 494-502.	0.6	6
726	Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?. <i>ESMO Open</i> , 2022, 7, 100536.	2.0	13
727	The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8125.	1.8	9
728	Current and emerging therapies for neuroendocrine prostate cancer. , 2022, 238, 108255.		13
729	Neoadjuvant treatment in ovarian cancer: New perspectives, new challenges. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
730	Health-related quality of life analysis in ovarian cancer clinical trials involving PARP inhibitors: a critical methodological perspective. <i>Quality of Life Research</i> , 0, , .	1.5	1
731	Maintenance therapy for newly diagnosed epithelial ovarian cancer – a review. <i>Journal of Ovarian Research</i> , 2022, 15, .	1.3	11
732	Understanding the needs and perspectives of ovarian cancer patients when considering PARP inhibitor maintenance therapy: Findings from two online community events. <i>Gynecologic Oncology Reports</i> , 2022, 43, 101050.	0.3	1
733	Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. <i>Lancet Oncology</i> , The, 2022, 23, e374-e384.	5.1	45
734	A lung adenocarcinoma patient with <i>ROS1</i> fusion and <i>NBN</i> germline mutation achieves long progression-free survival from sintilimab combined with niraparib after failure of <i>ROS1</i> inhibitors: a case report. <i>Annals of Translational Medicine</i> , 2022, .	0.7	1
735	Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
736	CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 107-116.	0.8	9
737	Long-term survival of a <i>BRCA2</i> mutation carrier following second ovarian cancer relapse using PARPi therapy: A case report. <i>Molecular and Clinical Oncology</i> , 2022, 17, .	0.4	1

#	ARTICLE	IF	CITATIONS
739	Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology/Young Academy of Gynecologic Oncology/Arbeitsgemeinschaft Gynäkologische Onkologie intergroup analysis. <i>International Journal of Gynecological Cancer</i> , 0, , ijgc-2022-003637.	1.2	0
740	A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2022, , .	0.6	2
742	PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8412.	1.8	19
743	Are Women with Antecedent Low-Grade Cytology and \leqCIN2 Findings in Colposcopy Being Overmanaged?. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2022, 44, 1054-1060.	0.3	1
744	Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant. <i>Clinical Cancer Research</i> , 2022, 28, 4660-4668.	3.2	2
745	Real-World Data on Newly Diagnosed BRCA-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database. <i>Cancers</i> , 2022, 14, 4040.	1.7	0
746	Regional Variations in Clinical Trial Outcomes in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 879-886.e2.	2.3	2
747	Immunotherapy in Ovarian Cancer. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2022, 70, .	1.0	8
748	Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma. <i>Genes</i> , 2022, 13, 1398.	1.0	1
749	Mutational landscape of homologous recombination-related genes in small-cell lung cancer. <i>Cancer Medicine</i> , 2023, 12, 4486-4495.	1.3	5
751	What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
752	BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. <i>Cancers</i> , 2022, 14, 3888.	1.7	56
753	Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers. <i>Nature Communications</i> , 2022, 13, .	5.8	18
754	The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 49-71.	157.7	23
755	Neoadjuvant immunotherapy of locoregionally advanced solid tumors. , 2022, 10, e005036.		9
757	Japanese nationwide observational multicenter study of tumor $BRCA1$ variant testing in advanced ovarian cancer. <i>Cancer Science</i> , 2023, 114, 271-280.	1.7	6
760	Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms. <i>Current Hematologic Malignancy Reports</i> , 2022, 17, 254-265.	1.2	6
761	Disparities in Biomarker Testing in Ovarian Cancer: A Real-World Analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2022, , .	0.7	0

#	ARTICLE	IF	CITATIONS
762	A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland. <i>Familial Cancer</i> , 2023, 22, 135-149.	0.9	2
763	The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response. <i>Cells</i> , 2022, 11, 2361.	1.8	5
764	Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. <i>EClinicalMedicine</i> , 2022, 52, 101595.	3.2	14
765	KIAA1529 regulates RAD51 expression to confer PARP inhibitors resistance in ovarian cancer. <i>Translational Oncology</i> , 2022, 24, 101497.	1.7	2
766	Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours. <i>European Journal of Medicinal Chemistry</i> , 2022, 242, 114690.	2.6	7
767	A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006). <i>Journal of Clinical Oncology</i> , 2023, 41, 276-284.	0.8	42
768	Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
769	Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting. <i>Cancers</i> , 2022, 14, 4414.	1.7	7
771	Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis. <i>ESMO Open</i> , 2022, 7, 100558.	2.0	7
772	Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial. <i>ESMO Open</i> , 2022, 7, 100585.	2.0	13
773	Cost-Effectiveness Analysis of Germline and Somatic <i>BRCA</i> Testing in Patients With Advanced Ovarian Cancer. <i>Annals of Laboratory Medicine</i> , 2023, 43, 73-81.	1.2	3
774	Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211261.	1.4	5
775	Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset. <i>Life</i> , 2022, 12, 1355.	1.1	2
776	Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer. <i>Pharmacoeconomics - Open</i> , 2022, 6, 811-822.	0.9	4
777	Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer. <i>Cancers</i> , 2022, 14, 4219.	1.7	0
778	Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition. <i>Cancer Research Communications</i> , 2022, 2, 1244-1254.	0.7	7
780	Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers. <i>Clinical Cancer Research</i> , 2022, 28, 4714-4723.	3.2	15
781	PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2022, , .	0.9	1

#	ARTICLE	IF	CITATIONS
782	PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures. <i>Cancers</i> , 2022, 14, 4751.	1.7	4
783	Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10503.	1.8	4
784	EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). <i>Future Oncology</i> , 2022, 18, 3481-3492.	1.1	8
785	Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
786	Novel approach of desensitization in allergic reaction to Olaparib. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 967-970.	0.5	1
787	Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 609-617.	0.8	127
788	Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 1254-1263.	1.2	14
789	Using Patient-Derived Xenograft (PDX) Models as a "Black Box"™ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial. <i>Cancers</i> , 2022, 14, 4649.	1.7	1
790	HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
791	Carcinomas With Concurrent Involvement of the Endometrium and Uterine Adnexa" Implications for Pathological Diagnosis and Clinical Management in Current Practice. <i>AJSP Review and Reports</i> , 2022, 27, 212-221.	0.0	0
792	PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer. , 0, , .		0
793	Primary Treatment Results in Patients with Ovarian, Fallopian or Peritoneal Cancer" Results of a Clinical Cancer Registry Database Analysis in Germany. <i>Cancers</i> , 2022, 14, 4638.	1.7	1
794	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in an Australian institution: lessons from 20"years"™ experience. <i>BMC Surgery</i> , 2022, 22, .	0.6	1
795	Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignancies. <i>Platelets</i> , 2022, 33, 1312-1313.	1.1	3
796	Corrected Allele Frequency of BRCA1/2 Mutations Is an Independent Prognostic Factor for Treatment Response to PARP-Inhibitors in Ovarian Cancer Patients. <i>Journal of Personalized Medicine</i> , 2022, 12, 1467.	1.1	1
797	Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers. <i>Fundamental and Clinical Pharmacology</i> , 2023, 37, 194-214.	1.0	1
798	Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer. <i>Future Oncology</i> , 0, , 00-00.	1.1	0
800	HE4 and CA125 serum biomarker monitoring in women with epithelial ovarian cancer. <i>Tumor Biology</i> , 2022, 44, 205-213.	0.8	7

#	ARTICLE	IF	CITATIONS
801	Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
802	PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond. <i>Cancers</i> , 2022, 14, 4332.	1.7	17
803	In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay. <i>Pathologica</i> , 2022, 114, 288-294.	1.3	18
804	Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival. <i>Cancers</i> , 2022, 14, 4621.	1.7	3
805	Epithelial ovarian cancer: Review article. <i>Cancer Treatment and Research Communications</i> , 2022, 33, 100629.	0.7	26
806	Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge. <i>Advances in Therapy</i> , 2022, 39, 5289-5299.	1.3	6
807	APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas. <i>Annals of Oncology</i> , 2022, 33, 1284-1295.	0.6	22
808	High detection rate from genetic testing in BRCA-negative women with familial epithelial ovarian cancer. <i>Genetics in Medicine</i> , 2022, , .	1.1	2
809	Characteristics of homologous recombination repair pathway genes mutation in ovarian cancers. , 2022, 1, 220-228.		0
810	Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors. <i>Journal of Clinical Oncology</i> , 2023, 41, 935-936.	0.8	2
811	Reply to C. Marchetti et al. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	0
812	22nd meeting of the European Society of Gynaecological Oncology (ESGO 2021) report. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1363-1369.	1.2	4
813	Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience. <i>Clinical Cancer Research</i> , 2022, 28, 5211-5220.	3.2	7
814	Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1105-1117.	1.0	7
815	Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial. <i>European Urology</i> , 2023, 83, 82-89.	0.9	5
816	Treatment of Advanced-Stage Ovarian Cancer. , 2022, , 105-119.		0
817	Personalized Treatment in Ovarian Cancer. <i>Comprehensive Gynecology and Obstetrics</i> , 2022, , 1-19.	0.0	0
818	Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan. <i>Journal of Gynecologic Oncology</i> , 2022, 34, .	1.0	2

#	ARTICLE	IF	CITATIONS
819	Prognostic Value of Tumor-microenvironment-associated Genes in Ovarian Cancer. <i>BIO Integration</i> , 2023, 4, .	0.9	0
820	How Genome-Wide Analysis Contributes to Personalized Treatment in Cancer, Including Gynecologic Cancer?. <i>Comprehensive Gynecology and Obstetrics</i> , 2022, , 115-132.	0.0	0
821	Clinical Relevance of BRCA1/2 Pathogenic Variants and Impaired DNA Repair Pathways in Ovarian Carcinomas. <i>Comprehensive Gynecology and Obstetrics</i> , 2022, , 59-76.	0.0	0
823	Clinical impact of soluble Neuropilin-1 in ovarian cancer patients and its association with its circulating ligands of the HGF/c-MET axis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
825	<i>Ad hoc</i>Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline<i>BRCA</i>Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects. <i>Cancer Research Communications</i> , 2022, 2, 1436-1444.	0.7	2
826	Is there a role for secondary debulking in ovarian cancer? A review of the current literature. <i>Current Opinion in Obstetrics and Gynecology</i> , 2023, 35, 1-5.	0.9	3
827	State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report. <i>JCO Precision Oncology</i> , 2022, , .	1.5	2
828	Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by an Expert Group from Middle East and North Africa Region. <i>Current Women's Health Reviews</i> , 2022, 19, .	0.1	0
829	The current role of secondary cytoreductive surgery for recurrent ovarian cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
830	Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1649-1675.	1.6	23
831	Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit:) Tj ETQq0 0 OrpBT /Overlock 10 TF		
832	Small molecule inhibitors targeting the cancers. <i>MedComm</i> , 2022, 3, .	3.1	25
833	Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1410-1418.	1.2	8
834	Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis. <i>Gynecologic Oncology</i> , 2022, 167, 547-556.	0.6	11
835	Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	6
836	Editorial: Current innovations in GI-oncology: Where do we stand?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
837	Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance. <i>Gynecologic Oncology</i> , 2022, 167, 502-512.	0.6	1
838	Niraparib-induced STAT3 inhibition increases its antitumor effects. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1

#	ARTICLE	IF	CITATIONS
839	Germline Testing and Somatic Tumor Testing for BRCA1/2 Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?. JCO Precision Oncology, 2022, , .	1.5	5
840	Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Oncology, 0, 12, .	1.3	1
841	Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma. Frontiers in Oncology, 0, 12, .	1.3	11
842	Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective. European Journal of Cancer, 2023, 179, 136-146.	1.3	13
843	Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. Clinical Cancer Research, 2023, 29, 50-59.	3.2	8
844	Body composition as a predictor of chemotherapy-related toxicity in ovarian cancer patients: A systematic review. Frontiers in Oncology, 0, 12, .	1.3	3
845	Exploring the DNA damage response pathway for synthetic lethality. Genome Instability & Disease, 2023, 4, 98-120.	0.5	2
846	Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020. ESMO Open, 2022, 7, 100593.	2.0	2
847	NAD+ metabolism in peripheral neuropathic pain. Neurochemistry International, 2022, 161, 105435.	1.9	2
849	A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer. Biochemical Pharmacology, 2022, 206, 115329.	2.0	16
850	Molecular hallmarks of cancer. , 2023, , 489-505.e5.		0
851	Epithelial ovarian cancer. , 2023, , 250-281.e8.		0
852	Targeted therapy and molecular genetics. , 2023, , 464-488.e11.		0
853	A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors. International Journal of Clinical Oncology, 0, , .	1.0	0
854	Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer. Journal of Oncology Pharmacy Practice, 0, , 107815522211377.	0.5	0
855	Ovarian Cancer-Cell Pericellular Hyaluronan Deposition Negatively Impacts Prognosis of Ovarian Cancer Patients. Biomedicines, 2022, 10, 2944.	1.4	7
856	Overview on population screening for carriers with germline BRCA mutation in China. Frontiers in Oncology, 0, 12, .	1.3	3
858	Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction. Medicina (Lithuania), 2022, 58, 1611.	0.8	4

#	ARTICLE	IF	CITATIONS
859	Multidisciplinary considerations in the maintenance treatment of poly(ADP-ribose) polymerase inhibitors for homologous recombination-proficient, advanced-stage epithelial ovarian cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 8-16.	157.7	6
860	Maintenance therapy with a poly (ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: updated individual patient data and trial-level meta-analysis. <i>ESMO Open</i> , 2022, 7, 100632.	2.0	1
861	Society of Gynecologic Oncology Journal Club: Controversial conversations in gynecologic cancer – Navigating maintenance therapy for homologous recombinant proficient ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2022, 44, 101103.	0.3	0
862	Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. <i>British Journal of Cancer</i> , 2023, 128, 342-353.	2.9	17
863	Homologous Recombination Deficiency in Triple-Negative Breast Cancer: Potential Benefit of a New Target. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	0
864	Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma. <i>Communications Biology</i> , 2022, 5, .	2.0	4
865	Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14242.	1.8	0
866	Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2023, 168, 135-143.	0.6	0
867	Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study. <i>Gynecologic Oncology</i> , 2023, 169, 118-124.	0.6	6
868	NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer. <i>Biomarkers in Medicine</i> , 0, , .	0.6	0
869	Design and reporting of phase III oncology trials with prospective biomarker validation. <i>Journal of the National Cancer Institute</i> , 0, , .	3.0	1
870	[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study. <i>Clinical Cancer Research</i> , 2023, 29, 1515-1527.	3.2	6
871	Clinical Significance of Tie-2-Expressing Monocytes/Macrophages and Angiopoietins in the Progression of Ovarian Cancer – State-of-the-Art. <i>Cells</i> , 2022, 11, 3851.	1.8	0
872	DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14672.	1.8	26
873	Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. <i>Annals of Oncology</i> , 2023, 34, 152-162.	0.6	18
874	Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality. <i>Cancers</i> , 2022, 14, 5795.	1.7	4
875	Guidance on the management of adverse reactions induced by poly(ADP-ribose) polymerase inhibitors. <i>Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences</i> , 2022, 51, 765-774.	0.1	0
876	Efficacy of oral ferric citrate hydrate treatment for anemia caused by niraparib: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, .	0.4	2

#	ARTICLE	IF	CITATIONS
877	A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. <i>Scientific Reports</i> , 2022, 12, .	1.6	14
878	Editorial: Molecular pathology and computational image analyses in gynecologic malignancies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
879	Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial. <i>International Journal of Clinical Oncology</i> , 2023, 28, 163-174.	1.0	1
880	Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
881	Cost-effectiveness of PARP inhibitors in malignancies: A systematic review. <i>PLoS ONE</i> , 2022, 17, e0279286.	1.1	1
882	Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥ 65 years from the PAOLA-1/ENGOT-ov25 trial. <i>European Journal of Cancer</i> , 2023, 181, 42-52.	1.3	5
883	Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations. <i>BMC Cancer</i> , 2022, 22, .	1.1	2
884	A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study. <i>EClinicalMedicine</i> , 2022, 54, 101767.	3.2	6
885	Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (<scp>Joâ€ECAG</scp>) ovarian study. <i>Molecular Genetics & Genomic Medicine</i> , 2023, 11, .	0.6	1
886	Parameter estimation of Weibull distribution for the number of days between drug administration and early onset adverse event. <i>Journal of Biopharmaceutical Statistics</i> , 0, , 1-14.	0.4	2
887	Switch Maintenance Therapy for Metastatic Urothelial Carcinoma. <i>Bladder Cancer</i> , 2022, 8, 359-369.	0.2	0
888	Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!. <i>Cancers</i> , 2023, 15, 43.	1.7	8
889	CCNE1 and survival of patients with tuboâ€ovarian highâ€grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. <i>Cancer</i> , 2023, 129, 697-713.	2.0	7
890	Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
891	CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	2
892	Mass spectrometry imaging in gynecological cancers: the best is yet to come. <i>Cancer Cell International</i> , 2022, 22, .	1.8	0
893	Number Needed to Treat in Trials of Targeted Therapies for Advanced Ovarian Cancer. <i>JAMA Network Open</i> , 2022, 5, e2245077.	2.8	2
894	The potential of PARP inhibitors in targeted cancer therapy and immunotherapy. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	12

#	ARTICLE	IF	CITATIONS
895	Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2023, 18, 463-475.	0.5	24
896	Towards Personalized Management of Ovarian Cancer. <i>Cancer Management and Research</i> , 0, Volume 14, 3469-3483.	0.9	4
897	AML and MDS associated with PARP inhibitor treatment of ovarian cancer. <i>Gynecologic Oncology</i> , 2023, 171, 162-163.	0.6	1
898	Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative. <i>International Journal of Gynecological Cancer</i> , 0, , ijgc-2022-004160.	1.2	0
899	Targeting DNA damage response pathways in cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 78-94.	12.8	158
900	Molecular Targeted Therapy in Oncology Focusing on DNA Repair Mechanisms. <i>Archives of Medical Research</i> , 2022, 53, 807-817.	1.5	1
901	IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. <i>BMC Cancer</i> , 2022, 22, .	1.1	0
902	Fortgeschrittenes Ovarialkarzinom: Niraparib plus Bevacizumab verbessert das Überleben. , 0, , .		0
903	Advances in small molecule maintenance therapies for high-grade serous ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 65-72.	0.9	1
904	Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. <i>Journal of Ovarian Research</i> , 2023, 16, .	1.3	8
905	Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 571-576.	1.2	0
906	Current Issues in the Management of Patients With Newly Diagnosed Advanced-Stage High-Grade Serous Carcinoma of the Ovary. <i>JCO Oncology Practice</i> , 0, , .	1.4	0
907	Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations. <i>Human Genomics</i> , 2023, 17, .	1.4	3
908	STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer. , 2023, 11, e005627.		17
909	PARP inhibitor olaparib induced differential protein expression in cervical cancer cells. <i>Journal of Proteomics</i> , 2023, , 104823.	1.2	0
910	Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations. <i>Annals of Pharmacotherapy</i> , 0, , 106002802211491.	0.9	0
911	Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study. <i>British Journal of Cancer</i> , 2023, 128, 1095-1104.	2.9	5
912	A novel defined risk signature of endoplasmic reticulum stress-related genes for predicting the prognosis and immune infiltration status of ovarian cancer. <i>Journal of Zhejiang University: Science B</i> , 2023, 24, 64-77.	1.3	5

#	ARTICLE	IF	CITATIONS
913	Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society. <i>Tumori</i> , 2023, 109, 490-495.	0.6	1
914	Association of Genomic Instability Score, Tumor Mutational Burden, and Tumor-Infiltrating Lymphocytes as Biomarkers in Uterine Serous Carcinoma. <i>Cancers</i> , 2023, 15, 528.	1.7	0
915	Diagnostic and Therapeutic Pathway of Advanced Ovarian Cancer with Peritoneal Metastases. <i>Cancers</i> , 2023, 15, 407.	1.7	2
917	Disparity in the era of personalized medicine for epithelial ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211480.	1.4	1
918	Proteomic Discovery of Plasma Protein Biomarkers and Development of Models Predicting Prognosis of High-Grade Serous Ovarian Carcinoma. <i>Molecular and Cellular Proteomics</i> , 2023, 22, 100502.	2.5	5
919	Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors. <i>Seminars in Immunopathology</i> , 0, , .	2.8	2
920	Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01). <i>Gynecologic Oncology</i> , 2023, 170, 19-24.	0.6	3
921	Enrollment of Racial and Ethnic Minoritized Groups in Gynecologic Oncology Clinical Trials: A Review of the Scope of the Problem, Contributing Factors, and Strategies to Improve Inclusion. <i>Clinical Obstetrics and Gynecology</i> , 2023, 66, 22-35.	0.6	6
922	Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme. <i>European Journal of Cancer</i> , 2023, 182, 3-14.	1.3	3
923	Paradigm change in urological, gynaecological and breast cancer management: A new practice-changing data from ASCO 2022 annual meeting. <i>Cancer Treatment and Research Communications</i> , 2023, 35, 100677.	0.7	1
924	Serous Tumors of the Ovary. <i>Encyclopedia of Pathology</i> , 2023, , 1-12.	0.0	0
925	Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis. <i>American Journal of Therapeutics</i> , 2023, 30, e36-e55.	0.5	4
926	Honeycomb-like Structured Film, a Novel Therapeutic Device, Suppresses Tumor Growth in an In Vivo Ovarian Cancer Model. <i>Cancers</i> , 2023, 15, 237.	1.7	0
927	Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	8
928	Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study. <i>Anticancer Research</i> , 2023, 43, 653-662.	0.5	1
929	Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer. <i>Cancers</i> , 2023, 15, 818.	1.7	9
930	PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 812-822.	1.2	1
931	Immunotherapy for Gynecologic Cancer. , 2023, , 1-19.		0

#	ARTICLE	IF	CITATIONS
932	Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. <i>Molecular Cell</i> , 2023, 83, 660-680.	4.5	10
933	Is Reflex Germline BRCA1/2 Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?. <i>Cancers</i> , 2023, 15, 730.	1.7	1
934	Discussing maintenance therapy for ovarian, peritoneal, and fallopian tube cancers. <i>Annals of Translational Medicine</i> , 2023, .	0.7	0
935	Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
936	PARP inhibitors, use early in the first-line maintenance therapy setting but with caution. <i>Annals of Translational Medicine</i> , 2023, 11, 272-272.	0.7	1
937	Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
938	Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial. <i>JCO Precision Oncology</i> , 2023, , .	1.5	13
939	Myeloid neoplasms post PARP inhibitors for ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 598-606.	1.2	5
940	Therapeutic effect of haploidentical peripheral blood stem cell treatment on relapsed/refractory ovarian cancer. <i>Bulletin Du Cancer</i> , 2023, 110, 285-292.	0.6	1
941	Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches. <i>Journal of Personalized Medicine</i> , 2023, 13, 284.	1.1	5
942	The relationship between PARP inhibitors with the relapse and leukemisation of lymphomas: a case report. <i>AME Case Reports</i> , 0, .	0.2	0
944	Safety and management of niraparib monotherapy in ovarian cancer clinical trials. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 971-981.	1.2	4
945	Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention. <i>Biomolecules</i> , 2023, 13, 653.	1.8	0
946	Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?. <i>Gynecologic Oncology Reports</i> , 2023, 46, 101173.	0.3	0
947	The evolving landscape of antibody-drug conjugates in gynecologic cancers. <i>Cancer Treatment Reviews</i> , 2023, 116, 102546.	3.4	13
948	Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma. <i>Translational Oncology</i> , 2023, 31, 101638.	1.7	0
949	Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial. <i>Gynecologic Oncology</i> , 2023, 172, 121-129.	0.6	2
950	Web-based tool for cancer family history collection: A prospective randomized controlled trial. <i>Gynecologic Oncology</i> , 2023, 173, 22-30.	0.6	4

#	ARTICLE	IF	CITATIONS
951	Real-world outcomes associated with use of front-line bevacizumab in ovarian cancer. <i>Journal of Cancer Policy</i> , 2023, 36, 100421.	0.6	2
952	The Role of PARP Inhibitors in the Treatment of Advanced Epithelial Ovarian Carcinoma. , 2022, , .		0
953	Recent Advances in Gynaecological Oncology. , 2022, , 475-494.		0
954	Epithelial Ovarian Cancer. , 2022, , 291-323.		1
955	Shedding Light on PARP Inhibitor Response through Functional Imaging. <i>Clinical Cancer Research</i> , 2023, 29, 1384-1386.	3.2	0
956	Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer. <i>Gynecologic Oncology</i> , 2023, 170, 221-228.	0.6	1
957	Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis. <i>Journal of Obstetrics and Gynaecology</i> , 2023, 43, .	0.4	4
958	Management of patients with advanced epithelial ovarian cancer: a European survey. <i>Archives of Gynecology and Obstetrics</i> , 0, , .	0.8	0
959	Immunotherapeutic Approaches in Ovarian Cancer. <i>Current Issues in Molecular Biology</i> , 2023, 45, 1233-1249.	1.0	5
960	WGS Data Collections: How Do Genomic Databases Transform Medicine?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3031.	1.8	2
961	Homologous recombination inquiry through ovarian malignancy investigations: <scp>JGOG3025</scp> Study. <i>Cancer Science</i> , 2023, 114, 2515-2523.	1.7	3
962	Suppression of GCH1 Sensitizes Ovarian Cancer and Breast Cancer to PARP Inhibitor. <i>Journal of Oncology</i> , 2023, 2023, 1-16.	0.6	0
963	Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study. <i>Cancers</i> , 2023, 15, 1032.	1.7	1
964	Synergistic effect of <scp>PARP</scp> inhibitor and <scp>BRD4</scp> inhibitor in multiple models of ovarian cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2023, 27, 634-649.	1.6	3
965	Survival outcomes in patients with <i>BRCA</i> mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 922-928.	1.2	2
966	Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 929-936.	1.2	1
967	Dostarlimab: From preclinical investigation to drug approval and future directions. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	2
968	Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF- κ B-Triggered SASP in Cancer-Associated Fibroblasts. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 447-458.	1.9	4

#	ARTICLE	IF	CITATIONS
969	Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma. <i>EMBO Molecular Medicine</i> , 2023, 15, .	3.3	5
970	A Review of the Latest Advancements in Ovarian Cancer Care Featured at ESMO 2022. <i>European Medical Journal Oncology</i> , 0, , 2-12.	0.0	2
972	Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency. <i>Genomics, Proteomics and Bioinformatics</i> , 2023, , .	3.0	2
973	Apatinib plus pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. <i>Cancer Research Statistics and Treatment</i> , 2022, 5, 793.	0.1	0
974	Deep Learning Provides a New Magnetic Resonance Imaging-Based Prognostic Biomarker for Recurrence Prediction in High-Grade Serous Ovarian Cancer. <i>Diagnostics</i> , 2023, 13, 748.	1.3	2
975	Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 1588.	1.0	1
976	Impact of complete surgical staging on survival of patients with early-stage (FIGO I or II) ovarian cancer: Data from the Cote d'Or Registry of Gynecological Cancers from 1998 to 2015. <i>Bulletin Du Cancer</i> , 2023, 110, 352-359.	0.6	1
977	Amplified therapeutic targets in high-grade serous ovarian carcinoma – a review of the literature with quantitative appraisal. <i>Cancer Gene Therapy</i> , 2023, 30, 955-963.	2.2	1
978	Human PARP1 substrates and regulators of its catalytic activity: An updated overview. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	5
979	Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma. , 2023, 11, e005968.		17
980	The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1645-1647.	3.2	3
982	Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study. <i>Anticancer Research</i> , 2023, 43, 1265-1272.	0.5	0
983	Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides <i>BRCA1</i> and <i>BRCA2</i> as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies. <i>Anticancer Research</i> , 2023, 43, 967-981.	0.5	4
984	A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer. <i>Gynecologic Oncology</i> , 2023, 171, 106-113.	0.6	7
985	Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311576.	1.4	3
986	BRCA Mutations – The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4982.	1.8	1
987	Molecular typing guiding treatment and prognosis of endometrial cancer. <i>Gynecology and Obstetrics Clinical Medicine</i> , 2023, 3, 7-17.	0.2	1
988	Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis. <i>ESMO Open</i> , 2023, 8, 101154.	2.0	2

#	ARTICLE	IF	CITATIONS
989	The biology and treatment of leiomyosarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 184, 103955.	2.0	1
990	Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2023, 91, 247-256.	1.1	0
991	Personalized Systemic Therapies in Hereditary Cancer Syndromes. <i>Genes</i> , 2023, 14, 684.	1.0	4
992	Therapy-related Myeloid Neoplasms Following PARP Inhibitors Letter. <i>Clinical Cancer Research</i> , 2023, 29, 1157-1157.	3.2	0
993	Outcomes and endpoints of relevance in gynecologic cancer clinical trials. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 323-332.	1.2	3
994	Association between Preoperative 18-FDG PET-CT SUVmax and Next-Generation Sequencing Results in Postoperative Ovarian Malignant Tissue in Patients with Advanced Ovarian Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 2287.	1.0	0
995	Integrating antibody drug conjugates in the management of gynecologic cancers. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 420-429.	1.2	8
996	Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 431-443.	1.2	11
997	Overcoming PARP inhibitor resistance in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 364-376.	1.2	4
998	CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data. <i>Cancers</i> , 2023, 15, 1823.	1.7	2
999	Engineering Bifunctional Calcium Alendronate Gene Delivery Nanoneedle for Synergistic Chemo/Immuno Therapy Against HER2 Positive Ovarian Cancer. <i>Advanced Science</i> , 2023, 10, .	5.6	2
1001	Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
1002	Th2 cells infiltrating high-grade serous ovarian cancer: a feature that may account for the poor prognosis. <i>Journal of Gynecologic Oncology</i> , 2023, 34, .	1.0	3
1003	Mechanism of PARP inhibitor resistance and potential overcoming strategies. <i>Genes and Diseases</i> , 2024, 11, 306-320.	1.5	7
1004	Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer. <i>Bulletin Du Cancer</i> , 2024, 111, 277-284.	0.6	2
1005	Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma. <i>Journal of Ovarian Research</i> , 2023, 16, .	1.3	2
1006	Targeting BRCA mutant biliary tract cancer: Current evidence and future perspectives. <i>Journal of Digestive Diseases</i> , 2023, 24, 85-97.	0.7	3
1007	Randomized Clinical Trials: Pitfalls in Design, Analysis, Presentation, and Interpretation. <i>Medical Radiology</i> , 2023, , .	0.0	0

#	ARTICLE	IF	CITATIONS
1008	Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance. <i>Oncology and Therapy</i> , 2023, 11, 245-261.	1.0	1
1009	Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era—Is it time for a new paradigm shift? A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2023, 187, 77-86.	1.3	4
1010	Ovarian Cancer Biomarkers: Immunohistochemical Surrogates for Molecular Alterations. , 2022, , 1-30.		0
1011	Hypoxia-Related lncRNA Prognostic Model of Ovarian Cancer Based on Big Data Analysis. <i>Journal of Oncology</i> , 2023, 2023, 1-14.	0.6	1
1012	Real-world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non-interventional study in China. <i>Cancer Communications</i> , 0, , .	3.7	1
1013	Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus. <i>Journal of Gynecologic Oncology</i> , 0, 34, .	1.0	0
1014	The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7293.	1.8	2
1015	Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG3012 trial. <i>Cancer</i> , 2023, 129, 1846-1855.	2.0	2
1016	Clinical Relevance of <i>BRCA1</i> Promoter Methylation Testing in Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 3124-3129.	3.2	4
1017	Comment on “Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer”™. (<i>Ther Adv Med Oncol</i> . 2021 Sep 30;13:17588359211049639). <i>Therapeutic Advances in Medical Oncology</i> . 2023, 15, 175883592311685.	1.4	1
1019	Author response to “Comment on “Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer”™. (<i>Ther Adv Med Oncol</i> . 2021 Sep 30;13:17588359211049639)”. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311685.	1.4	0
1020	Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors. <i>Journal of the National Cancer Institute</i> , 2023, 115, 831-837.	3.0	2
1021	PARP Inhibitors in Breast and Ovarian Cancer. <i>Cancers</i> , 2023, 15, 2357.	1.7	9
1022	Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 1253-1259.	1.2	2
1023	Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database. <i>Drugs and Aging</i> , 2023, 40, 397-405.	1.3	1
1024	Targeted therapy. , 2023, , 205-411.		0
1025	Use of PARP inhibitors in prostate cancer: from specific to broader application. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	2
1026	Intraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial. , 2023, 2, .		6

#	ARTICLE	IF	CITATIONS
1027	An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group. <i>Journal of Gynecologic Oncology</i> , 2023, 34, .	1.0	0
1096	Managing Adverse Effects of Novel Therapeutic Agents in Gynecologic Malignancies. <i>SN Comprehensive Clinical Medicine</i> , 2023, 5, .	0.3	0
1110	High-Grade Serous Carcinoma. , 2023, , 53-72.		0
1126	Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability. <i>Chromosome Research</i> , 2023, 31, .	1.0	1
1131	DNA as the main target in radiotherapyâ€™a historical overview from first isolation to anti-tumour immune response. <i>Strahlentherapie Und Onkologie</i> , 2023, 199, 1080-1090.	1.0	3
1142	Molecular Characterization of Single Circulating Tumor Cells in Breast and Ovarian Cancer. <i>Current Cancer Research</i> , 2023, , 327-358.	0.2	0
1144	Liquid biopsy in ovarian cancer: advantages and limitations for prognosis and diagnosis. , 2023, 40, .		0
1146	Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options. <i>Drugs</i> , 2023, 83, 1365-1385.	4.9	0
1147	Heterogeneity and treatment landscape of ovarian carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 820-842.	12.5	3
1169	Recent Advances in Gynecological Malignancies: Focus on ASCO 2023. <i>Oncology and Therapy</i> , 0, , .	1.0	0
1179	Non-serous and Rare Histologies of Ovarian Cancer. , 2023, , 43-51.		0
1180	Epithelial Ovarian Cancer: High Grade Serous. , 2023, , 15-30.		0
1213	Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer. <i>Cancer Treatment and Research</i> , 2023, , 71-89.	0.2	0
1218	Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges. <i>Cancer Treatment and Research</i> , 2023, , 143-170.	0.2	0
1219	Development of Homologous Recombination Functional Assays for Targeting the DDR. <i>Cancer Treatment and Research</i> , 2023, , 43-70.	0.2	0
1220	Combination DNA Damage Response (DDR) Inhibitors to Overcome Drug Resistance in Ovarian Cancer. <i>Cancer Treatment and Research</i> , 2023, , 189-206.	0.2	0
1240	Mutual Feedback Between Gynecological HBOC Practice and Cancer Genomic Medicine. , 2023, , 47-56.		0
1241	Handling Germline Findings in Ovarian Cancer Cases. , 2023, , 129-141.		0

#	ARTICLE	IF	CITATIONS
1270	Serous Tumors, Pathology of the Ovary. Encyclopedia of Pathology, 2023, , 554-564.	0.0	0
1275	Homologous repair deficiency and PARP inhibitors in cancer management. , 2024, , 257-274.		0
1292	Case report: Minimally invasive primary debulking surgery for advanced stage epithelial ovarian cancer. Frontiers in Oncology, 0, 14, .	1.3	0
1308	Advances in the Medical Management of Ovarian Cancer. , 2023, , 345-396.		0
1309	The Molecular Classification of Ovarian Cancer and Implication for Treatment. , 2023, , 285-315.		0